🏷

Classifications

Harrison's Chapter

📘

Definitions

1

ILAE 2022 Syndrome Definition of EIDEE

The ILAE Task Force on Nosology and Definitions defines EIDEE as an epilepsy syndrome with seizure onset at or before 3 months of age, frequent drug-resistant seizures of multiple types (tonic, clonic, myoclonic, focal, epileptic spasms), an abnormal interictal EEG (burst-suppression, multifocal epileptiform discharges or hypsarrhythmia), an abnormal neurological examination, and developmental impairment. The syndrome subsumes the previously separate Ohtahara syndrome and early myoclonic encephalopathy. The 2022 position statement publishes per-syndrome tables of mandatory features, cautionary alerts and exclusionary features, and provides guidance for syndrome diagnosis in resource-limited settings where EEG, MRI and genetic testing may be unavailable.

DIAGNOSTIC_CRITERIA Syndrome-level diagnostic criteria applied to neonates and infants with seizure onset in the first three months of life.

Inclusion criteria

Seizure onset at or before 3 months of age The mandatory age-at-onset criterion that defines the syndrome.
Frequent, typically drug-resistant seizures Multiple seizure types may occur - tonic, clonic, myoclonic, focal and epileptic spasms.
Abnormal interictal EEG Burst-suppression, multifocal epileptiform discharges, or hypsarrhythmia.
Abnormal neurological examination Typically axial hypotonia with or without limb hypertonia or spasticity.
Developmental impairment Impairment beyond that attributable to the epileptiform activity alone, reflecting the developmental as well as the epileptic component.

Exclusion criteria

Acute provoked (acute symptomatic) neonatal seizures Seizures secondary to an acute reversible insult such as hypoglycaemia, hypocalcaemia or acute infection, without an ongoing epilepsy.
Self-limited neonatal or infantile epilepsy Normal development and normal interictal EEG with spontaneous remission - the self-limited arm of the ILAE neonatal/infantile classification.
Seizure onset after 3 months of age Later onset points to infantile epileptic spasms syndrome, Dravet syndrome, or another infantile syndrome.

Show evidence (2 references)

PMID:35503712 SUPPORT Other

"The tables summarize mandatory features, cautionary alerts, and exclusionary features for the common syndromes."

Establishes that the 2022 position statement is the source of the mandatory/cautionary/exclusionary criterion structure used here. Evidence source is OTHER because this is a consensus position statement.

PMID:35503712 SUPPORT Other

"Syndromes are separated into self-limited syndromes, where there is likely to be spontaneous remission and developmental and epileptic encephalopathies, diseases where there is developmental impairment related to both the underlying etiology independent of epileptiform activity and the epileptic..."

States the self-limited versus DEE dichotomy that underpins the exclusion of self-limited neonatal epilepsy from EIDEE. Evidence source is OTHER because this is a consensus position statement.

Notes: The exact mandatory/alert/exclusionary tables are in the full text of the position statement; only the abstract is available in the reference cache, so the criteria listed here are the syndrome features documented in the abstract, the MONDO:0800491 definition, and the primary cohort literature.

👪

Inheritance

3

Autosomal dominant inheritance HP:0000006

The majority of genetically resolved EIDEE is caused by heterozygous de novo variants in dominant channel and synaptic genes (KCNQ2, STXBP1, SCN2A, SCN8A, GNAO1, KCNT1). Two thirds of pathogenic findings in a prospective EIDEE cohort followed dominant inheritance.

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:39237642 SUPPORT Other

"LOF de novo KCNQ2 variants cause neonatal-onset EIDEE"

Illustrates the de novo dominant mechanism for the prototypical EIDEE gene. The same sentence continues that inherited KCNQ2 variants instead cause self-limited seizures; the snippet is truncated because the source PDF carries a reference marker immediately after "EIDEE".

Autosomal recessive inheritance HP:0000007

A minority of EIDEE is autosomal recessive, most notably the metabolic and mitochondrial causes (SLC25A22, biotinidase deficiency, ALDH7A1, PNPO). Recessive causes are enriched in consanguineous populations. One third of pathogenic findings in a prospective EIDEE cohort were recessive.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:19780765 SUPPORT Human Clinical

"we describe a novel SLC25A22 mutation in an unrelated patient born from first cousin Algerian parents and presenting severe epileptic encephalopathy characterized by an EEG with SB, hypotonia, microcephaly"

A homozygous SLC25A22 variant in a consanguineous family is the archetypal recessive, metabolic cause of neonatal EE with suppression-burst.

X-linked inheritance HP:0001417

CDKL5 and ARX are X-linked causes of EIDEE. ARX mutations act through disrupted GABAergic interneuron migration and maturation, producing X-linked infantile spasms syndrome and, at the severe end, early-infantile encephalopathy with suppression-burst.

X-linked inheritance

Show evidence (1 reference)

PMID:22565167 PARTIAL Other

"A spectrum of mutations in the Aristaless-Related Homeobox gene (ARX) has been linked to ISSX, and downstream targets of this interneuron-expressed transcription factor are being defined."

Establishes ARX as an interneuron-expressed transcription factor whose mutation spectrum underlies X-linked infantile spasms syndrome (ISSX). Marked PARTIAL rather than SUPPORT because the snippet itself names neither the X-linked mode of inheritance in words nor EIDEE; the X-linkage and the EIDEE-severity end of the ARX spectrum are stated in the body of the source rather than in this sentence. Evidence source is OTHER because this is a review article.

◈

Mechanistic Hypotheses

1

Suppressing epileptiform activity in EIDEE recovers a separable share of developmental potential

eidee_epileptic_component_reversibility EMERGING

Evidence balance 1 partial

The DEE construct implies that the epileptic component of the encephalopathy is, in principle, modifiable: if the epileptiform activity independently degrades development, then abolishing it should yield developmental gains over and above the fixed developmental encephalopathy. There are clear proofs of principle in other DEEs (withdrawal of contraindicated sodium-channel blockers in Dravet syndrome, EEG normalization in Landau-Kleffner syndrome). Whether this holds for EIDEE specifically is unresolved, because at onset before three months the two components act on the same developmental window and cannot be dissociated clinically. In KCNQ2-EIDEE, for example, seizures remit in more than half of patients in early life yet impairment remains severe to profound - which argues that the developmental component dominates in at least some genotypes.

Pathograph links

Recurrent Drug-Resistant Seizures -> Developmental and Epileptic Encephalopathy INDIRECT UNKNOWN INTERMEDIATES The epileptic-encephalopathy arm: the additive, in-principle-modifiable contribution of the epileptiform activity itself to the developmental outcome, over and above the direct developmental arm.

Show evidence (1 reference)

PMID:39237642 PARTIAL Other

"there are clear examples where improvement of seizure control or resolution of interictal EEG abnormalities ameliorate cognitive outcome"

Supports the general premise for the DEEs while the same source notes it is difficult to determine any additive effect of seizures on cognitive outcome, which is why this is recorded as an emerging hypothesis rather than an established mechanism.

?

Discussions and Knowledge Gaps

2

Does the ILAE 2022 merge of Ohtahara syndrome and early myoclonic encephalopathy into EIDEE discard clinically actionable structure, given that the historical split tracked etiology (structural versus metabolic) and that the two arms differ in predominant seizure type?

KNOWLEDGE GAP OPEN eidee_ohtahara_eme_merge_residual_structure

Attached to

pathophysiology#Etiologic Lesion of the Immature Brain

The 2012 review that argued for unification did so on the basis of overlapping clinical presentation, prognosis and EEG signature. But the 2023 prospective EIDEE cohort found that etiologic group is strongly predictive within EIDEE: tonic seizures are enriched in the genetic/unknown group (risk ratio 0.66 for the vitamin-responsive/structural group) while clonic seizures are enriched in the vitamin-responsive/structural group (risk ratio 1.36), and severe developmental delay differs by an odds ratio of 57 between the groups. That is close to the axis the Ohtahara/EME split was tracking. If the seizure-type-plus-etiology structure is reproducible, EIDEE may need documented etiologic strata rather than a single undifferentiated syndrome.

Proposed experiments

Etiology-stratified prospective EIDEE cohort with seizure-type and EEG phenotyping

exp_eidee_etiology_stratified_seizure_type_cohort

Prospective multi-centre EIDEE cohorts reporting seizure type, interictal EEG pattern and outcome stratified by etiologic group, powered to test whether the tonic versus myoclonic/clonic distinction is independent of etiology.

Decision criterion

If seizure type remains associated with the historical Ohtahara/EME split after adjustment for etiologic group, the merged syndrome is hiding reproducible structure.

Retrospective reclassification of historical Ohtahara and EME series

exp_eidee_historical_series_reclassification

Reclassify published Ohtahara syndrome and early myoclonic encephalopathy case series against the ILAE 2022 EIDEE criteria with modern genomic and metabolic testing, to determine how cleanly the historical labels map onto contemporary etiologic strata.

Decision criterion

A clean mapping would indicate the historical labels were etiologic proxies; a poor mapping would support the merge.

Show evidence (1 reference)

PMID:23044011 SUPPORT Other

"Newer understandings of underlying etiologies of these conditions may support the previously suggested concept that they represent a single spectrum of disease rather than two distinct disorders."

States the unification argument that the ILAE 2022 reclassification adopted. Evidence source is OTHER because this is a review article.

In EIDEE specifically, what share of the eventual developmental impairment is attributable to the epileptiform activity itself and is therefore potentially modifiable by seizure and EEG control, versus fixed by the underlying etiology?

KNOWLEDGE GAP OPEN eidee_developmental_vs_epileptic_component

Attached to

pathophysiology#Developmental and Epileptic Encephalopathy

The DEE construct asserts two separable contributors, but at onset before three months both act on the same developmental window and the DEE Primer states the distinction is often impossible to make. The natural experiment - KCNQ2-EIDEE, where seizures remit in over half of patients by age 9 months to 4 years yet impairment remains severe to profound - suggests the developmental component dominates for at least some genotypes. Resolving this determines whether aggressive seizure suppression in the neonatal period is developmentally worthwhile or only symptomatically so, and it is the central unstated assumption behind every EIDEE precision-therapy trial endpoint.

Proposed experiments

Longitudinal correlation of interictal epileptiform burden with developmental outcome

exp_eidee_epileptiform_burden_vs_developmental_quotient

Genotype-stratified longitudinal studies correlating quantitative interictal epileptiform burden in the first six months with developmental quotient at 2 and 5 years, controlling for etiologic group.

Decision criterion

An independent association between epileptiform burden and later developmental quotient after adjusting for genotype would establish a modifiable epileptic component.

Outcome comparison by early EEG normalization

exp_eidee_eeg_normalization_outcome_comparison

Compare developmental outcome between EIDEE infants achieving early complete EEG normalization and matched infants with persistent epileptiform activity but equivalent clinical seizure control.

Decision criterion

Better outcome in the EEG-normalized arm at equivalent seizure control would isolate the epileptic contribution to the encephalopathy.

Show evidence (1 reference)

PMID:20437616 SUPPORT Human Clinical

"Seizures generally cease between ages nine months and four years."

Establishes the seizure-remission-without-developmental-recovery pattern in KCNQ2-EIDEE that motivates this question; the same GeneReviews entry records that moderate-to-profound developmental impairment is present.

⚙

Pathophysiology

8

Etiologic Lesion of the Immature Brain

EIDEE is a final common electroclinical phenotype rather than a single disease, and the upstream lesion is heterogeneous: a pathogenic variant in an ion-channel, synaptic, transcriptional or metabolic gene; a structural malformation of cortical development or acquired perinatal brain injury; or an inborn error of metabolism, frequently a vitamin-responsive one. In a prospective EIDEE cohort an etiology was established in 83% of infants - genetic in 50%, structural in 19% and metabolic in 14%, with all metabolic cases vitamin-responsive.

Neuron CL:0000540

Regulation of Membrane Potential GO:0042391 ⚠ ABNORMAL Chemical Synaptic Transmission GO:0007268 ⚠ ABNORMAL

cerebral cortex UBERON:0000956

Downstream

Reduced Kv7.2/Kv7.3 M-Current

Increased Persistent Sodium Current

Impaired Synaptic Vesicle Release and Inhibitory Circuit Formation

Excitation-Inhibition Imbalance in Immature Cortical Networks

Developmental and Epileptic Encephalopathy The developmental-encephalopathy arm. The etiologic lesion degrades development directly, independently of any seizure, by perturbing developmental processes and neural cell function in the immature brain. This edge is required for the entry to model EIDEE as a developmental AND epileptic encephalopathy; without it the pathograph would assert - against the ILAE construct and against this entry's own outcome-node description - that all developmental impairment is seizure-mediated.

Show evidence (2 references)

PMID:38074073 SUPPORT Human Clinical

"patients were further classified into four aetiological groups: genetic (50%), structural (19%), metabolic (14%; all were vitamin responsive) and unknown"

Quantifies the etiologic heterogeneity of the trigger node in the largest prospective EIDEE-specific cohort.

PMID:35503712 SUPPORT Other

"The principal aim of this proposal, consistent with the 2017 ILAE Classification of the Epilepsies, is to support epilepsy diagnosis and emphasize the importance of classifying epilepsy in an individual both by syndrome and etiology."

The ILAE position statement establishes that syndrome and etiology are orthogonal axes, which is exactly why EIDEE has a single conserved mechanism chain with a heterogeneous trigger. Evidence source is OTHER because this is a consensus position statement rather than primary data.

Reduced Kv7.2/Kv7.3 M-Current

KCNQ2 and KCNQ3 form the heterotetrameric M-channel that regulates neuronal excitability. De novo loss-of-function KCNQ2 variants reduce the M-current that repolarizes neurons after firing, removing a brake on repetitive discharge and producing neonatal-onset EIDEE. The same gene's inherited variants instead cause self-limited familial neonatal epilepsy, so the lesion is dose- and mechanism-dependent rather than gene-dependent. This node is deliberately separated from the sodium-channel gain-of-function node below: the two are opposite-direction lesions converging on the same downstream imbalance, and only one of them is a sodium-channel-blocker target.

Neuron CL:0000540

Potassium Ion Transmembrane Transport GO:0071805 ↓ DECREASED

voltage-gated potassium channel activity GO:0005249 ↓ DECREASED

Downstream

Excitation-Inhibition Imbalance in Immature Cortical Networks

Show evidence (3 references)

PMID:39237642 SUPPORT Other

"LOF de novo KCNQ2 variants cause neonatal-onset EIDEE"

States the loss-of-function KCNQ2 to EIDEE relationship directly, using the EIDEE label. Evidence source is OTHER because the source is a Nature Reviews Disease Primers review article.

PMID:39237642 SUPPORT Other

"KCNQ3 and KCNQ2 form the heterotetrameric M-"

Identifies the Kv7.2/Kv7.3 heterotetrameric M-channel as the molecular substrate. The quote is truncated at "M-" because the source PDF hyphenates "M-channel" across a line break. Evidence source is OTHER because the source is a review article.

PMID:39237642 PARTIAL Other

"KCNQ2 EIDEE typically causes severe to profound impairment"

Establishes the clinical severity of the KCNQ2 arm. Marked PARTIAL because it speaks to outcome rather than to the M-current mechanism this node asserts. Evidence source is OTHER because the source is a review article.

Increased Persistent Sodium Current

Gain-of-function variants in the sodium-channel alpha subunits SCN2A, SCN8A, SCN3A and rarely SCN1A slow fast inactivation, accelerate its recovery, or increase persistent inward sodium current, raising intrinsic neuronal excitability. This is the arm of the EIDEE channelopathy spectrum that responds to sodium-channel-blocker therapy, and it is why the functional direction of a sodium-channel variant - not the gene name - determines the prescription.

Neuron CL:0000540

Sodium Ion Transmembrane Transport GO:0035725 ↑ INCREASED

voltage-gated sodium channel activity GO:0005248 ↑ INCREASED

Downstream

Excitation-Inhibition Imbalance in Immature Cortical Networks

Show evidence (2 references)

PMID:28379373 SUPPORT Human Clinical

"mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current"

Establishes the gain-of-function biophysical signature specific to SCN2A variants presenting with epilepsy onset before three months.

PMID:32090326 SUPPORT Human Clinical

"Individuals with gain-of-function SCN2A/3A/8A missense variants or CNV duplications share similar characteristics, most frequently present with early onset epilepsy (<3 months)"

Extends the gain-of-function-to-early-onset relationship across SCN2A, SCN3A and SCN8A as a class.

Impaired Synaptic Vesicle Release and Inhibitory Circuit Formation

The second major genetic class is the synaptopathies and interneuronopathies. STXBP1 (Munc18-1) haploinsufficiency disrupts SNARE-mediated synaptic vesicle docking and fusion, reducing evoked neurotransmitter release; STXBP1 was the single commonest gene in both a prospective EIDEE cohort and a burst-suppression cohort. ARX loss disrupts the specification and tangential migration of cortical GABAergic interneurons, so the inhibitory circuitry itself is built wrong. Recessive SLC25A22 loss abolishes mitochondrial glutamate carrier activity, coupling a metabolic lesion to the same neurotransmission endpoint.

GABAergic interneuron CL:0000617 Glutamatergic neuron CL:0000679

Synaptic Vesicle Exocytosis GO:0016079 ↓ DECREASED Neuron Migration GO:0001764 ⚠ ABNORMAL Glutamate Secretion GO:0014047 ⚠ ABNORMAL

Downstream

Excitation-Inhibition Imbalance in Immature Cortical Networks

Show evidence (3 references)

PMID:29217410 SUPPORT Model Organism

"Munc18-1 haploinsufficiency impairs learning and memory by reduced synaptic vesicular release in a model of Ohtahara syndrome"

A mouse model of STXBP1/Munc18-1 haploinsufficiency, explicitly framed as an Ohtahara syndrome model, links the genetic lesion to reduced synaptic vesicular release. Evidence source is MODEL_ORGANISM; this mechanism is not directly demonstrated in human brain tissue.

PMID:32247221 SUPPORT Human Clinical

"with the most commonly diagnosed gene being STXBP1 (n = 13, 27.1 %), followed by KCNQ2 (n = 5, 10.4 %), SCN2A (n = 5, 10.4 %)"

Shows the synaptic gene STXBP1 is the single commonest molecular diagnosis in early-onset epileptic encephalopathy with burst suppression, ahead of the channel genes.

PMID:19780765 SUPPORT Human Clinical

"We showed that this patient carried a homozygous p.G236W SLC25A22 mutation which alters a highly conserved amino acid and completely abolishes the glutamate carrier's activity in vitro."

Ties a recessive metabolic lesion (mitochondrial glutamate carrier loss) to the same neurotransmission endpoint in neonatal EE with suppression-burst.

Excitation-Inhibition Imbalance in Immature Cortical Networks

Whatever the upstream lesion, the convergent consequence is a shift of the balance between glutamatergic excitation and GABAergic inhibition toward net excitation, occurring in cortical networks that are still being assembled. The immature-brain context matters: the same lesion acting later produces a different, usually milder, syndrome, and the age factor is the common denominator that determines whether the resulting electroclinical picture is EIDEE, infantile epileptic spasms syndrome, or Lennox-Gastaut syndrome.

GABAergic neuron CL:0000617

GABA Signaling Pathway GO:0007214 ↓ DECREASED

cerebral cortex UBERON:0000956

Downstream

Burst-Suppression and Hypersynchronous Cortical Discharge

Show evidence (3 references)

PMID:11751020 PARTIAL Human Clinical

"Mutual transition suggests the same pathophysiology among three syndromes and the age factor should be considered as the common denominator responsible for the manifestation of each of their own specific clinico-electrical features."

Ohtahara's own case series argues that the same underlying pathophysiology, filtered through developmental age, yields EIDEE, West syndrome or Lennox-Gastaut syndrome - the rationale for the developmental-context half of this node. Marked PARTIAL because it does not address the excitation/inhibition claim itself.

PMID:30764523 SUPPORT Other

"Those considerations gave rise to the excitation/inhibition (E/I) imbalance theory, whereby increased excitation, decreased inhibition, or both favor a hyperexcitable state and an increased propensity for seizure generation and epileptogenesis."

Defines the E/I imbalance paradigm asserted by this node, in a paediatric-epilepsy-specific source. This is the same evidence the epilepsy_excitation_inhibition_imbalance module uses for the node this one conforms to. Evidence source is OTHER because this is a review article.

PMID:33808762 PARTIAL Other

"In the brain, GABA is a major inhibitory neurotransmitter and plays a pivotal role in maintaining E/I balance."

Supports the GABAergic arm of the imbalance. Marked PARTIAL because the source is about autism spectrum disorders rather than EIDEE; it is used only for the general neurotransmitter claim, matching its use in the epilepsy module. Evidence source is OTHER because this is a review article.

Burst-Suppression and Hypersynchronous Cortical Discharge

Net excitatory bias in the immature cortex produces hypersynchronous population discharge whose electrographic expression in EIDEE is characteristically a suppression-burst pattern: bursts of 1-3 seconds of high-voltage activity alternating with a nearly flat suppression phase of 2-5 seconds, present regardless of the circadian cycle. Tonic spasms occur concomitantly with the bursts. Burst-suppression is characteristic but not obligatory - in a prospective EIDEE cohort it was present in 42%, with multifocal discharges in 30% and hypsarrhythmia in 13%.

Neuron CL:0000540

Regulation of Membrane Potential GO:0042391 ⚠ ABNORMAL

cerebral cortex UBERON:0000956

Downstream

Recurrent Drug-Resistant Seizures

Show evidence (2 references)

PMID:11751020 SUPPORT Human Clinical

"Bursts of 1-3s duration alternate with nearly flat suppression phase of 2-5s at an approximately regular rate; 5-10s of burst-burst interval."

Gives the quantitative electrographic definition of the suppression-burst pattern that is the signature effector readout of this node.

PMID:11751020 SUPPORT Human Clinical

"Tonic spasms appear concomitant with bursts."

Couples the clinical seizure to the electrographic burst, establishing that the burst is the hypersynchronous discharge event.

Recurrent Drug-Resistant Seizures

Hypersynchronous discharge is expressed clinically as frequent, recurrent, unprovoked seizures - multiple daily in most infants - that are typically refractory to multiple antiseizure medications in combination. This is the epilepsy proper, and it is separable from the encephalopathy that follows it: seizures remit in some genotypes without developmental recovery.

Suppressing epileptiform activity in EIDEE recovers a separable share of developmental potential

Downstream

Developmental and Epileptic Encephalopathy The epileptic-encephalopathy arm: the additive, in-principle-modifiable contribution of the epileptiform activity itself to the developmental outcome, over and above the direct developmental arm.

Show evidence (2 references)

PMID:20437616 SUPPORT Human Clinical

"KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features."

Documents recurrent multiple-daily seizures as the clinical expression in the prototypical genetic EIDEE.

PMID:20437616 SUPPORT Human Clinical

"Seizures may be resistant to multiple ASMs alone or in combination."

Documents the drug-resistant character of the recurrent seizures.

Developmental and Epileptic Encephalopathy

The clinical endpoint is a two-component encephalopathy. A developmental encephalopathy arises directly from the etiology and impairs development independently of any seizure; an epileptic encephalopathy is superimposed when the epileptiform activity itself further degrades cognition and behaviour beyond what the underlying pathology alone would produce. The distinguishing feature of EIDEE specifically is that these two components cannot be separated: onset at or before three months means the etiology and the epileptiform activity act on the same window of development. This is the mechanistic reason EIDEE is defined as a developmental AND epileptic encephalopathy rather than a pure epileptic encephalopathy, and the reason seizure control alone does not restore development. Module note: this node declares no conforms_to. The epilepsy_excitation_inhibition_imbalance module terminates at recurrent unprovoked seizures (conformed above by Recurrent Drug-Resistant Seizures); the two-component developmental-plus-epileptic encephalopathy is EIDEE-specific content that lies beyond the module's chain. The module's "Seizure Generation and Epileptogenesis" node is likewise not separately instantiated: in EIDEE the epileptogenesis step is not clinically separable from the burst-suppression effector that precedes it, so splitting it out would create a node with no independent evidence.

Nervous System Development GO:0007399 ⚠ ABNORMAL

Show evidence (2 references)

PMID:39237642 SUPPORT Other

"developmental impairment and an EE, such as EIDEE, including Ohtahara syndrome and Early Myoclonic Encephalopathy"

The DEE Primer states that separating the developmental from the epileptic encephalopathy is often impossible in an infant under three months who presents with developmental impairment and an epileptic encephalopathy such as EIDEE - and, in the same clause, names Ohtahara syndrome and early myoclonic encephalopathy as instances of EIDEE.

PMID:39237642 SUPPORT Other

"beyond what might be expected from the underlying pathology alone, and that these can worsen over time"

The closing clause of the ILAE definition of an epileptic encephalopathy - that the epileptic activity itself contributes to impairment beyond what the underlying pathology alone would produce, and that this can worsen over time. This is the epileptic component superimposed on the developmental encephalopathy in this node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

13

Head and Neck 1

Microcephaly Microcephaly HP:0000252

Show evidence (1 reference)

PMID:19780765 SUPPORT Human Clinical

"an EEG with SB, hypotonia, microcephaly and abnormal electroretinogram"

Documents microcephaly as part of the neonatal EE with suppression-burst phenotype in a molecularly confirmed case.

Musculoskeletal 1

Abnormal Neurological Examination with Hypotonia Hypotonia HP:0001252

Show evidence (2 references)

PMID:38074073 PARTIAL Human Clinical

"tone abnormalities (Odds Ratio = 9; P = 0.0006)"

Quantifies tone abnormality as a discriminating feature of the genetic/unknown EIDEE groups. Marked PARTIAL because the cohort reports tone abnormalities as a class, not hypotonia specifically.

PMID:19780765 SUPPORT Human Clinical

"presenting severe epileptic encephalopathy characterized by an EEG with SB, hypotonia, microcephaly and abnormal electroretinogram"

Documents hypotonia as part of the neonatal EE with suppression-burst phenotype.

Nervous System 7

Tonic Seizures and Tonic Spasms FREQUENT Tonic seizure HP:0032792

Show evidence (2 references)

PMID:11751020 SUPPORT Human Clinical

"Ohtahara syndrome (OS) is characterized by frequent tonic spasms, with or without clustering, of early onset within a few months of life, and a suppression-burst (S-B) pattern in electroencephalography (EEG). Tonic spasms occur in not only waking but also sleeping state in most cases."

Defines frequent tonic spasms as a core feature occurring in most cases, supporting the FREQUENT band.

PMID:38074073 PARTIAL Human Clinical

"vitamin responsive/structural aetiology patients were less likely to have tonic seizures (Risk Ratio = 0.66; P = 0.04)"

Shows tonic seizures are etiology-dependent within EIDEE; marked PARTIAL because it quantifies a between-group contrast rather than the overall frequency.

Burst-Suppression EEG FREQUENT EEG with burst suppression HP:0010851

Show evidence (2 references)

PMID:11751020 SUPPORT Human Clinical

"S-B pattern is persistently observed regardless of circadian cycle."

Records the persistence of the suppression-burst pattern across the circadian cycle, the feature that distinguishes it from transient burst-suppression seen in other contexts.

PMID:20437616 SUPPORT Human Clinical

"At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity"

GeneReviews confirms that burst-suppression is one of two alternative onset EEG patterns in the prototypical genetic EIDEE, supporting FREQUENT rather than OBLIGATE.

Hypsarrhythmia Hypsarrhythmia HP:0002521

Show evidence (2 references)

PMID:11751020 SUPPORT Human Clinical

"proceed concomitantly with EEG transition from S-B to hypsarrhythmia at around age 3-6 months"

Documents the suppression-burst to hypsarrhythmia transition that accompanies evolution to West syndrome.

PMID:27905812 SUPPORT Human Clinical

"EEG abnormalities can include focal epileptic activity, burst suppression, hypsarrhythmia, or generalized spike-and-slow waves."

GeneReviews for the commonest EIDEE gene lists hypsarrhythmia as one of the alternative interictal EEG patterns.

Drug-Resistant Epilepsy FREQUENT Seizure HP:0001250

Course: PROGRESSIVE

Show evidence (2 references)

PMID:38074073 SUPPORT Human Clinical

"only vitamin responsive aetiology had a statistically significant positive effect on seizure control (P = 0.02)"

Shows that outside the vitamin-responsive subgroup no factor predicted seizure control, i.e. drug resistance is the norm.

PMID:20437616 SUPPORT Human Clinical

"Seizures may be resistant to multiple ASMs alone or in combination."

GeneReviews confirms multidrug resistance in the prototypical genetic EIDEE.

Severe to Profound Developmental Delay and Intellectual Disability VERY_FREQUENT Global developmental delay HP:0001263

Severity: SEVERE

Show evidence (2 references)

PMID:38074073 SUPPORT Human Clinical

"in the 'genetic/unknown' groups were more frequently observed to have severe developmental delay (Odds Ratio = 57; P < 0.0001)"

Quantifies severe developmental delay and its dependence on etiologic group.

PMID:33475165 SUPPORT Human Clinical

"All infants with EIEE or EIMFS had severe-profound delay or were deceased"

Population-based confirmation that severe-to-profound impairment is the rule, supporting VERY_FREQUENT.

Movement Disorder Abnormality of movement HP:0100022

Show evidence (2 references)

PMID:38074073 PARTIAL Human Clinical

"movement disorder (Odds Ratio = 19; P < 0.0001)"

Quantifies movement disorder as a discriminating feature of genetic EIDEE. Marked PARTIAL because the source reports movement disorder as a class, not dystonia specifically.

PMID:27905812 SUPPORT Human Clinical

"Other neurologic findings include abnormal tone, movement disorders (especially ataxia and dystonia), and behavioral issues and autism spectrum disorder."

GeneReviews for the commonest EIDEE gene lists dystonia and other movement disorders among the core neurological findings.

Autistic Behaviour Autistic behavior HP:0000729

Show evidence (2 references)

PMID:38074073 PARTIAL Human Clinical

"autistic behaviours (Odds Ratio = 37; P < 0.0001)"

Quantifies autistic behaviour as a discriminating outcome of the genetic/unknown EIDEE groups. Marked PARTIAL because the source reports a between-group odds ratio rather than a syndrome-wide frequency.

PMID:27905812 SUPPORT Human Clinical

"behavioral issues and autism spectrum disorder"

GeneReviews lists autism spectrum disorder among the neurological and behavioural findings in the commonest EIDEE gene.

Other 4

Seizure Onset at or Before Three Months of Age OBLIGATE Neonatal seizure HP:0032807

Show evidence (1 reference)

PMID:20437616 SUPPORT Human Clinical

"KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the first week of life"

Documents neonatal seizure onset in the prototypical genetic EIDEE. Frequency is OBLIGATE because onset at or before three months is part of the syndrome definition rather than an observed proportion.

Myoclonic Seizures Myoclonic seizure HP:0032794

Show evidence (2 references)

PMID:23044011 PARTIAL Other

"Ohtahara syndrome and early myoclonic encephalopathy are the earliest presenting of the epileptic encephalopathies."

Establishes early myoclonic encephalopathy as one of the two constituent presentations now unified as EIDEE. Marked PARTIAL because the snippet names the syndrome but does not itself describe myoclonus; the link from "early myoclonic encephalopathy" to myoclonic seizures as its defining seizure type is definitional rather than quoted. Evidence source is OTHER because this is a review article.

PMID:27905812 SUPPORT Human Clinical

"Seizure types can include infantile spasms; generalized tonic-clonic, clonic, or tonic seizures; and myoclonic, atonic, absence, and focal seizures."

GeneReviews for the commonest EIDEE gene lists myoclonic seizures among the seizure types seen, which is the direct evidence that myoclonus occurs in EIDEE rather than only in the historical EME label.

Focal Clonic Seizures Focal clonic seizure HP:0002266

Show evidence (2 references)

PMID:38074073 SUPPORT Human Clinical

"Clonic seizures were more common in the vitamin responsive/structural groups (Risk Ratio = 1.36; P = 0.05) as compared to patients with 'genetic/unknown' aetiologies."

Documents clonic seizures as a common EIDEE seizure type with an etiology-dependent distribution.

PMID:11751020 PARTIAL Human Clinical

"Partial seizures are observed in about one-third of cases."

Historical proportion of focal seizures in the original Ohtahara series. Marked PARTIAL because the source says "partial" (focal) without specifying a clonic semiology, so it supports the focal component of this phenotype but not the clonic component.

Structural Brain Abnormality on MRI FREQUENT Abnormal brain morphology HP:0012443

Show evidence (2 references)

PMID:38074073 SUPPORT Human Clinical

"MRI was abnormal in 35/80 patients (malformation observed in 16/35; 19/35 had non-specific changes that did not contribute to underlying aetiology)"

Quantifies the frequency and character of structural imaging abnormality in EIDEE, supporting a FREQUENT band for any abnormality.

PMID:11751020 SUPPORT Human Clinical

"Brain imagings reveal structural abnormalities including malformations, notably asymmetric lesions in most cases."

The original Ohtahara series reports structural abnormality including malformation in most cases.

🧬

Genetic Associations

10

STXBP1

Gene: STXBP1 hgnc:11444 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (1 reference)

PMID:27905812 SUPPORT Human Clinical

"The median age of onset of seizures is six weeks (range: 1 day to 13 years)."

GeneReviews confirms that the modal STXBP1 presentation falls inside the EIDEE onset window of three months.

KCNQ2

Gene: KCNQ2 hgnc:6296 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (2 references)

PMID:20437616 SUPPORT Human Clinical

"KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features."

GeneReviews describes the KCNQ2 neonatal-onset DEE phenotype, which falls squarely inside EIDEE.

PMID:39237642 SUPPORT Other

"LOF de novo KCNQ2 variants cause neonatal-onset EIDEE"

States the KCNQ2 loss-of-function to EIDEE relationship explicitly using the EIDEE label.

SCN2A

Gene: SCN2A hgnc:10588 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (1 reference)

PMID:28379373 SUPPORT Human Clinical

"truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers"

Establishes the genotype/onset-age/treatment-response correlation that makes SCN2A an EIDEE gene only in its gain-of-function form.

SCN8A

Gene: SCN8A hgnc:10596 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (3 references)

PMID:27559564 SUPPORT Human Clinical

"Epilepsy phenotypes include developmental and epileptic encephalopathy (DEE) associated with severe developmental delays and usually pharmacoresistant epilepsy with multiple seizure types"

GeneReviews establishes the severe, pharmacoresistant DEE end of the SCN8A phenotypic spectrum, the arm relevant to EIDEE.

PMID:27559564 SUPPORT Human Clinical

"Hypotonia and movement disorders including dystonia, ataxia, and choreoathetosis are common in some phenotypes."

GeneReviews documents the hypotonia and movement-disorder comorbidities that this entry curates as EIDEE phenotypes.

PMID:32090326 SUPPORT Human Clinical

"Individuals with gain-of-function SCN2A/3A/8A missense variants or CNV duplications share similar characteristics, most frequently present with early onset epilepsy (<3 months), and demonstrate good response to sodium channel blockers (SCBs)."

Groups SCN2A, SCN3A and SCN8A gain-of-function variants as a class presenting within the EIDEE onset window with a shared treatment response.

CDKL5

Gene: CDKL5 hgnc:11411 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (1 reference)

PMID:38603524 SUPPORT Human Clinical

"CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy (DEE) characterized by severe early-onset intractable epilepsy and motor, cognitive, visual, and autonomic disturbances."

GeneReviews establishes CDKL5 deficiency disorder as a severe early-onset developmental and epileptic encephalopathy.

GNAO1

Gene: GNAO1 hgnc:4389 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (1 reference)

PMID:39419567 SUPPORT Other

"CDKL5, CSNK2B, GABAAr, GNAO1, GRIN1"

Lists GNAO1 among the well-known genes linked to the DEEs. Evidence source is OTHER because this is a review article.

KCNT1

Gene: KCNT1 hgnc:18865 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (1 reference)

PMID:39419567 SUPPORT Other

"KCNQ2, KCNT1, NBEA, PCDH19, SCN1A, SCN2A, SCN8A, STXBP1"

Lists KCNT1 among the well-known genes linked to the DEEs. Evidence source is OTHER because this is a review article.

SLC25A22

Gene: SLC25A22 hgnc:19954 relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:19780765 SUPPORT Human Clinical

"Comparison of the clinical features of patients from both families suggests that SLC25A22 mutations are responsible for a novel clinically recognizable epileptic encephalopathy with SB."

Establishes SLC25A22 as a cause of neonatal epileptic encephalopathy with suppression-burst.

ARX

Gene: ARX hgnc:18060 relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:22565167 SUPPORT Other

"complex interactions between Arx and its binding partners and their effects on cell migration and maturation that can help explain the diversity of ARX phenotypes"

Establishes disrupted interneuron migration and maturation as the ARX mechanism. Evidence source is OTHER because this is a review article.

SCN1A

Gene: SCN1A hgnc:10585 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (1 reference)

PMID:39237642 SUPPORT Other

"patients with the non-Dravet, EIDEE phenotype due to GOF variants may respond to SCB, such as carbamazepine and phenytoin"

States the SCN1A gain-of-function EIDEE phenotype and its opposite treatment implication relative to Dravet syndrome.

💊

Medical Actions

9

Etiology-Guided Diagnostic Workup and Precision Treatment

Action: Targeted Therapy NCIT:C93352

Because EIDEE is defined electroclinically but treated etiologically, the single most consequential intervention is rapid etiologic diagnosis: video EEG, epilepsy-protocol brain MRI, targeted metabolic testing, and rapid trio exome or genome sequencing. Molecular diagnosis was achieved in 69% of tested infants in a prospective EIDEE cohort. The diagnosis then determines treatment direction - vitamin supplementation, sodium-channel blockade, channel opener, resective surgery or ketogenic diet - and the same gene can require opposite treatments depending on the functional direction of the variant.

Show evidence (1 reference)

PMID:38074073 SUPPORT Human Clinical

"A molecular diagnosis was achieved in 53 out of 77 patients tested (69%). Next-generation sequencing had a yield of 51%, while microarray had a yield of 14%."

Quantifies the diagnostic yield that makes an etiology-first strategy worthwhile in EIDEE.

Vitamin and Cofactor Trials for Treatable Metabolic Causes

Action: Pharmacotherapy NCIT:C15986

Agent: pyridoxine CHEBI:16709 biotin CHEBI:15956

A monitored empiric trial of pyridoxine (for ALDH7A1 pyridoxine-dependent epilepsy), pyridoxal 5'-phosphate (PNPO deficiency), folinic acid and biotin (biotinidase deficiency) is a priority in any infant presenting with EIDEE, because these are the only etiologies with a demonstrably favourable seizure outcome. In a prospective EIDEE cohort all metabolic causes were vitamin-responsive, and vitamin responsiveness was the only independently significant positive predictor of seizure control. Pyridoxine trials require cardiorespiratory monitoring because apnoea can occur.

Mechanism Target:

INHIBITS Etiologic Lesion of the Immature Brain — Cofactor supplementation corrects the underlying metabolic block in vitamin-responsive causes, removing the trigger rather than suppressing the downstream discharge.

Show evidence (2 references)

PMID:38074073 SUPPORT Human Clinical

"Patients with vitamin responsive epilepsies had the best probability of seizure control."

The cohort's headline treatment conclusion, directly supporting vitamin trials as the highest-yield intervention.

PMID:38074073 SUPPORT Human Clinical

"Metabolic testing was diagnostic in three out of 41 patients tested (all three had biotinidase deficiency)."

Identifies biotinidase deficiency as the specific treatable metabolic cause found in this cohort, supporting the biotin arm.

Sodium Channel Blocker Therapy for Gain-of-Function Channelopathies

Action: Pharmacotherapy NCIT:C15986

Agent: carbamazepine CHEBI:3387 phenytoin CHEBI:8107

Carbamazepine, phenytoin and related sodium-channel blockers are the prototype EIDEE precision therapy. In infants with gain-of-function SCN2A, SCN3A or SCN8A variants, and in KCNQ2 loss-of-function EIDEE, sodium-channel blockade is often markedly more effective than other antiseizure medications; the same drugs are contraindicated in SCN1A loss-of-function Dravet syndrome, where they aggravate seizures. Because EIDEE and Dravet syndrome can both be caused by SCN1A, the functional direction of the variant - not the gene name - must drive the prescription.

Mechanism Target:

INHIBITS Increased Persistent Sodium Current — Sodium-channel blockade directly counteracts the increased persistent inward sodium current produced by gain-of-function variants. The edge points at the sodium arm only: the KCNQ2 potassium arm is a loss-of-function lesion and its precision target is an M-channel opener, not a blocker.

Show evidence (3 references)

PMID:32090326 SUPPORT Human Clinical

"most frequently present with early onset epilepsy (<3 months), and demonstrate good response to sodium channel blockers (SCBs)"

Directly links the EIDEE onset window to sodium-channel-blocker responsiveness in gain-of-function sodium channelopathies.

PMID:28379373 SUPPORT Human Clinical

"the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective"

Quantitative clinical support for sodium-channel blockade specifically in the under-three-month onset group.

PMID:20437616 SUPPORT Human Clinical

"Seizure freedom is more likely achieved when receiving sodium channel blockers."

GeneReviews recommendation for KCNQ2 neonatal-onset DEE.

Conventional Antiseizure Medication

Action: Anticonvulsant Therapy NCIT:C64172

Agent: phenobarbital CHEBI:8069 levetiracetam CHEBI:6437 vigabatrin CHEBI:63638

Phenobarbital, levetiracetam, benzodiazepines, valproate and vigabatrin are the conventional first- and second-line antiseizure medications used while the etiology is being established and in the majority of infants for whom no precision option exists. Phenobarbital, valproic acid and vigabatrin are the most commonly used agents in STXBP1 encephalopathy, the commonest single-gene EIDEE. Roughly a quarter of STXBP1 patients are refractory to antiseizure medication altogether.

Mechanism Target:

INHIBITS Burst-Suppression and Hypersynchronous Cortical Discharge — Conventional antiseizure medications act symptomatically on network hypersynchrony rather than on the upstream etiologic lesion.

Show evidence (1 reference)

PMID:27905812 SUPPORT Human Clinical

"The most commonly used anti-seizure medications (ASMs) are phenobarbital, valproic acid, and vigabatrin. About 20% of individuals require more than one ASM and approximately 25% are refractory to ASM therapy."

GeneReviews for the commonest EIDEE gene names the conventional ASMs used and quantifies refractoriness.

Hormonal Therapy with ACTH or Corticosteroid

Action: Pharmacotherapy NCIT:C15986

Agent: corticotropin CHEBI:3892 prednisolone CHEBI:8378

Adrenocorticotropic hormone and high-dose corticosteroid are the standard of care once EIDEE evolves into infantile epileptic spasms syndrome (West syndrome), the commonest downstream syndrome, typically at 3-6 months as the EEG moves from suppression-burst to hypsarrhythmia. Hormonal therapy is far less consistently effective for EIDEE in its suppression-burst phase, and spasm-phase efficacy should not be read back onto the neonatal phase. No `target_mechanisms` edge is declared: the mechanism by which hormonal therapy suppresses spasms is not established, and asserting an edge into this entry's pathograph would overstate what is known.

Show evidence (2 references)

PMID:35765990 PARTIAL Human Clinical

"Treatments including ACTH and high dose prednisolone are more effective in achieving electroclinical and clinical remissions for infantile spasms."

Supports hormonal therapy for infantile spasms, the syndrome EIDEE characteristically evolves into. Marked PARTIAL because the evidence is for the spasms phase, not for EIDEE in its suppression-burst phase. Evidence source is HUMAN_CLINICAL: this is a network meta-analysis synthesising randomised trials in children, not a narrative review.

PMID:11751020 SUPPORT Human Clinical

"Characteristic age-dependent evolution from OS to West syndrome (WS) in many cases"

Establishes the evolution to West syndrome that makes hormonal therapy relevant to the EIDEE care pathway.

Ketogenic Diet

Action: Dietary Intervention NCIT:C15447

The ketogenic diet is used for antiseizure-medication-resistant EIDEE and is disease-targeted therapy in GLUT1 deficiency. It is feasible in neonates and young infants but requires close monitoring: in a neonatal series 40% had a good response while the diet had to be suspended in a further 40% because of serious adverse effects.

Mechanism Target:

INHIBITS Burst-Suppression and Hypersynchronous Cortical Discharge — Ketosis raises seizure threshold and suppresses network hypersynchrony; in GLUT1 deficiency it additionally bypasses the etiologic transport defect.

Show evidence (2 references)

PMID:37321250 SUPPORT Human Clinical

"Diet had a good response in four (40%) patients. In four patients, the ketogenic diet was suspended because of the onset of serious side effects."

Gives both the response rate and the tolerability limitation of the ketogenic diet in neonates with drug-resistant epilepsy.

PMID:37321250 SUPPORT Human Clinical

"The ketogenic diet is efficacious and safe in infants, but the early and aggressive management of adverse reactions is important to improve the safety and effectiveness of the ketogenic treatment."

The authors' overall conclusion on ketogenic diet use in this age group.

Epilepsy Surgery for Resectable Structural Lesions

Action: Surgical Procedure NCIT:C15329

Structural etiology accounts for roughly a fifth of EIDEE, and where a unifocal resectable lesion such as focal cortical dysplasia is identified, surgical resection can be transformative. In a burst-suppression EIDEE cohort, surgical resection was effective in patients with cortical dysplasia.

Mechanism Target:

INHIBITS Etiologic Lesion of the Immature Brain — Resection removes the structural lesion that is the etiologic trigger, rather than modulating the downstream network.

Show evidence (1 reference)

PMID:32247221 SUPPORT Human Clinical

"surgical resection proved to be effective in patients with cortical dysplasia"

Direct evidence for resective surgery in the structural subgroup of early-onset EE with burst suppression.

Multidisciplinary Supportive and Developmental Care

Action: Supportive Care NCIT:C15747

Because developmental impairment persists even when seizures improve, holistic care is essential: feeding and swallowing assessment with gastrostomy where needed, respiratory and sleep management, physiotherapy, occupational and speech/communication therapy, management of tone and movement disorders, vision and hearing services, seizure rescue planning, and psychosocial and palliative support.

Show evidence (1 reference)

PMID:27905812 SUPPORT Human Clinical

"Treatment per orthopedics, physical medicine and rehabilitation, physical therapy, and occupational therapy to help avoid contractures and falls, with positioning and mobility devices as needed."

GeneReviews management recommendations for the commonest EIDEE gene, representative of supportive care across the syndrome.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Most EIDEE-causing dominant variants are de novo, giving a low but non-zero recurrence risk; parental mosaicism raises that risk above the conventional germline-mosaicism estimate and can be detected with high-depth sequencing. Recessive and X-linked diagnoses carry standard recurrence risks and support cascade testing, prenatal testing and preimplantation genetic testing.

Show evidence (2 references)

PMID:20437616 SUPPORT Human Clinical

"Most individuals diagnosed with KCNQ2-NEO-DEE have a de novo pathogenic variant."

GeneReviews establishes the de novo origin that determines counselling for the prototypical genetic EIDEE.

PMID:39237642 SUPPORT Other

"high-depth sequencing of parental blood or salivary samples found that 8% of patients had a parent with low-level mosaicism"

Quantifies the parental-mosaicism rate that this counselling recommendation depends on, replacing what was previously an unsourced claim in the description. Tagged OTHER because this Nat Rev Dis Primers narrative review reports the 8% figure secondhand from its own reference 175 rather than as primary data, consistent with the other twelve items citing this review.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Early-Infantile Developmental and Epileptic Encephalopathy:

Dravet syndrome MONDO:0100135

Overlapping Features SCN1A loss-of-function DEE with onset typically at 5-6 months, prolonged febrile hemiclonic or generalized seizures, and initially normal development and EEG - all outside the EIDEE definition. The distinction is treatment-critical: sodium-channel blockers aggravate Dravet syndrome but may be the treatment of choice in gain-of-function EIDEE.

Distinguishing Features

Onset at 5-6 months rather than by 3 months
Normal development and normal interictal EEG before onset
Febrile, often prolonged hemiclonic seizures
SCN1A loss-of-function rather than gain-of-function

Show evidence (1 reference)

PMID:39237642 SUPPORT Other

"patients with the non-Dravet, EIDEE phenotype due to GOF variants may respond to SCB, such as carbamazepine and phenytoin"

Explicitly contrasts the EIDEE phenotype with Dravet syndrome at the level of SCN1A variant direction and drug response.

Infantile epileptic spasms syndrome (West syndrome) MONDO:0018097

Overlapping Features Epileptic spasms in clusters with hypsarrhythmia, typically presenting at 3-12 months. It is both a differential diagnosis and the commonest syndrome into which EIDEE evolves; the discriminator is age at onset and the interictal EEG pattern at presentation.

Distinguishing Features

Onset typically after 3 months
Hypsarrhythmia rather than suppression-burst at presentation
Epileptic spasms in clusters as the defining seizure type

Show evidence (1 reference)

PMID:33475165 SUPPORT Human Clinical

"West syndrome (WS) and "WS-like" epilepsy (infantile spasms without hypsarrhythmia or modified hypsarrhythmia) were the most common syndromes"

Population-based study distinguishing West syndrome from EIEE as separate syndromes with different incidences and outcomes.

Epilepsy of infancy with migrating focal seizures MONDO:0017385

Overlapping Features A distinct neonatal/infantile DEE defined by migrating focal seizures on EEG rather than suppression-burst, most often caused by KCNT1 gain-of-function. Curated separately in dismech as Epilepsy_of_Infancy_with_Migrating_Focal_Seizures; the MONDO term is bound here as well so that the differential boundary is machine-queryable. The binding uses MONDO:0017385 to match that sibling entry: MONDO:0100025 carries the obsoletion_candidate subset (the two terms share the NANDO:1200595 xref and are duplicate concepts), so MONDO:0017385 is the surviving MONDO class for EIMFS. preferred_term keeps the modern ILAE label.

Distinguishing Features

Ictal EEG shows seizures migrating between hemispheres
Interictal EEG does not show a persistent suppression-burst pattern
Strong association with KCNT1 gain-of-function

Show evidence (1 reference)

PMID:33475165 SUPPORT Human Clinical

"The incidence of epilepsy of infancy with migrating focal seizures (EIMFS) was 4.5/100 000 and of early infantile epileptic encephalopathy (EIEE) was 3.6/100 000."

Treats EIMFS and EIEE as separate, separately enumerated syndromes in a population-based cohort.

Self-limited (familial) neonatal epilepsy Not Yet Curated MONDO:0100023

Overlapping Features Neonatal seizures beginning in otherwise healthy infants in the first days of life that remit spontaneously in the first year, with normal development. Most commonly caused by inherited KCNQ2 variants - the same gene whose de novo loss-of-function variants cause EIDEE - which makes this the single most instructive EIDEE differential.

Distinguishing Features

Normal development and normal interictal EEG
Spontaneous remission between the first and sixth to twelfth month of life
Inherited rather than de novo KCNQ2 variant

Show evidence (1 reference)

PMID:20437616 SUPPORT Human Clinical

"KCNQ2-SLFNE is characterized by seizures that start in otherwise healthy infants between two and eight days after term birth and spontaneously disappear between the first and the sixth to 12th month of life."

GeneReviews contrasts the self-limited and DEE ends of the KCNQ2 continuum, which is exactly the differential at issue.

Pyridoxine-dependent and other vitamin-responsive epilepsies Not Yet Curated MONDO:0009945

Overlapping Features ALDH7A1 pyridoxine-dependent epilepsy, PNPO deficiency, folinic-acid responsive seizures and biotinidase deficiency present within the EIDEE window and satisfy the EIDEE criteria, but are separable by their dramatic response to the relevant vitamin or cofactor and carry a much better seizure prognosis. Curated separately as Pyridoxine-Dependent_Epilepsy. Empiric monitored vitamin trials should not be delayed pending genetic results. The binding deliberately uses the generic parent MONDO:0009945 rather than the ALDH7A1-specific MONDO:0020741 bound by that sibling entry, because this differential spans PNPO, folinic-acid-responsive and biotinidase deficiency as well as ALDH7A1; MONDO:0020741 is a child of MONDO:0009945, so the sibling entry still resolves under this term by subsumption.

Distinguishing Features

Dramatic seizure response to pyridoxine, pyridoxal 5'-phosphate, folinic acid or biotin
Best probability of seizure control of any EIDEE etiologic group

Show evidence (1 reference)

PMID:38074073 SUPPORT Human Clinical

"metabolic (14%; all were vitamin responsive)"

All metabolic EIDEE causes in this prospective cohort were vitamin-responsive, which is what makes this differential actionable.

{ }

Source YAML

click to show

name: Early-Infantile Developmental and Epileptic Encephalopathy
creation_date: "2026-07-31T23:35:00Z"
description: >-
  Early-infantile developmental and epileptic encephalopathy (EIDEE) is the
  ILAE 2022 neonatal/infantile-onset epilepsy syndrome defined by frequent,
  drug-resistant seizures beginning at or before 3 months of age, an abnormal
  interictal EEG (classically burst-suppression, but also multifocal
  epileptiform discharges or hypsarrhythmia), an abnormal neurological
  examination, and developmental impairment. An identifiable structural,
  genetic, or metabolic cause is found in up to 80% of affected infants.

  Nosology - the point of this entry. EIDEE is a reclassification, not a new
  disease. In the 2022 ILAE Task Force on Nosology and Definitions position
  statement on epilepsy syndromes with onset in neonates and infants, the two
  historically separate entities Ohtahara syndrome (early infantile epileptic
  encephalopathy with suppression-bursts, defined by tonic spasms plus a
  persistent suppression-burst EEG) and early myoclonic encephalopathy (EME,
  defined by erratic/fragmentary myoclonus plus suppression-burst, classically
  metabolic in origin) were folded into the single syndrome EIDEE. The
  unification followed a long-standing argument that the clinical presentation,
  prognosis, and electroencephalographic signature of the two overlap so
  extensively that they represent one spectrum rather than two disorders, and
  that the historical split tracked presumed etiology (structural for Ohtahara,
  metabolic for EME) more reliably than it tracked electroclinical phenotype.
  MONDO:0800491 carries "Ohtahara syndrome", "early myoclonic encephalopathy",
  "EIEE", and "early infantile epileptic encephalopathy" as exact synonyms,
  reflecting this merge.

  Scope and boundaries. EIDEE is an age-at-onset electroclinical syndrome,
  etiologically heterogeneous by design. It should not be conflated with (a)
  the numbered OMIM/MONDO "DEE1..DEEn" (historically "EIEE1..n") series, which
  are gene-defined diseases curated separately in dismech (KCNQ2-DEE, STXBP1
  encephalopathy, CDKL5 deficiency disorder, SCN2A-DEE, SCN8A-DEE, GNAO1-DEE
  and others); (b) Genetic_Developmental_and_Epileptic_Encephalopathy, the
  etiology-defined umbrella spanning all ages of onset; or (c) the later-onset
  infantile syndromes Infantile_Spasms (infantile epileptic spasms syndrome),
  Dravet_syndrome, and Epilepsy_of_Infancy_with_Migrating_Focal_Seizures, from
  which EIDEE is separated by its onset at or before 3 months and its
  interictal EEG. This entry captures the syndrome-level definition, the shared
  mechanism, the etiologic spectrum, and the etiology-guided treatment
  approach; gene-specific variant spectra and natural history belong on the
  gene-specific entries.
category: Genetic
disease_term:
  preferred_term: early-infantile DEE
  term:
    id: MONDO:0800491
    label: early-infantile DEE
parents:
- Epilepsy
synonyms:
- EIDEE
- early-infantile developmental and epileptic encephalopathy syndrome
- Ohtahara syndrome
- early infantile epileptic encephalopathy with suppression-bursts
- early myoclonic encephalopathy
- EME
- EIEE
- early infantile epileptic encephalopathy
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    notes: >-
      EIDEE is a neonatal/infantile-onset epilepsy syndrome; its care sits in
      paediatric neurology/epileptology.
    evidence:
    - reference: PMID:35503712
      reference_title: "ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The International League Against Epilepsy (ILAE) Task Force on Nosology
        and Definitions proposes a classification and definition of epilepsy
        syndromes in the neonate and infant with seizure onset up to 2 years of
        age.
      explanation: >-
        EIDEE is defined within the ILAE neonatal/infantile epilepsy-syndrome
        classification, placing it squarely in the neurologic chapter. Evidence
        source is OTHER because this is a consensus position statement.
notes: >-
  Boundary handling with adjacent dismech entries. Ohtahara syndrome and early
  myoclonic encephalopathy are curated here as synonyms of EIDEE rather than as
  separate entries, matching both the ILAE 2022 reclassification and the
  MONDO:0800491 synonym set. Dravet_syndrome (MONDO:0100135) stays a distinct
  entry: its onset is typically at 5-6 months with febrile hemiclonic seizures
  and a normal early EEG, which places it outside the "seizures at or before 3
  months with abnormal interictal EEG and abnormal neurological examination"
  EIDEE definition. Note the one deliberate crossover recorded below: rare
  SCN1A gain-of-function variants produce a non-Dravet EIDEE phenotype with
  onset by three months, and that phenotype is EIDEE, not Dravet syndrome, with
  the opposite sodium-channel-blocker recommendation. Infantile_Spasms
  (infantile epileptic spasms syndrome) is likewise kept separate; it is the
  commonest downstream syndrome EIDEE evolves into, and the transition is
  modelled here as a progression phase rather than by merging the two entries.
  Gene-level entries (KCNQ2_Developmental_and_Epileptic_Encephalopathy,
  STXBP1_Encephalopathy, CDKL5_Deficiency_Disorder,
  SCN2A-Related_Developmental_and_Epileptic_Encephalopathy,
  SCN8A-Related_Developmental_and_Epileptic_Encephalopathy,
  GNAO1-Related_Developmental_and_Epileptic_Encephalopathy) are referenced from
  the genetic section rather than duplicated.
  Undetermined_Early_Onset_Epileptic_Encephalopathy (MONDO:0018614) is the
  closest neighbouring entry and is also kept separate: it is an
  etiology-undetermined grouping holding numbered DEE subtypes, whereas EIDEE is
  a positively defined electroclinical syndrome with a specified onset window
  and an identifiable cause in up to 80% of cases.

  Relationship to the EIDEE Grouping. A companion Grouping,
  `kb/groupings/Early_Infantile_Developmental_and_Epileptic_Encephalopathies`
  (PR #7480), models the same ILAE syndrome as an auditable *union* over the
  molecularly defined member Disease entries whose documented onset falls inside
  the three-month window (KCNQ2, SCN2A, STXBP1, CDKL5, UGDH). The two are
  complementary, not duplicative, and follow the pattern CLAUDE.md records for
  diabetes mellitus, where a Grouping carries a skos mapping to a MONDO umbrella
  term while a retained umbrella Disease carries that term as its
  `disease_term`. The division of labour: a Grouping cannot carry
  `pathophysiology`, `phenotypes`, `prevalence`, `treatments` or `definitions`,
  so the conserved mechanism chain, the ILAE 2022 diagnostic criteria, the
  Ohtahara/EME reclassification story, the epidemiology and the
  etiology-guided treatment approach live here; the explicit, evaluator-checkable
  membership boundary lives there. The Grouping asserts `skos:broadMatch` to
  MONDO:0800491 precisely because it covers only a subset of the syndrome's
  genetic, structural and metabolic etiologies - this entry covers the whole
  syndrome concept, including the structural and metabolic causes that have no
  gene-level member entry. The same argument the
  Genetic_Developmental_and_Epileptic_Encephalopathy entry makes for being an
  umbrella Disease rather than a Grouping applies here.

  Deliberate omissions. `clinical_trials` is empty: the EIDEE-relevant trials
  surfaced by deep research are all gene-specific (SCN2A ASO, KCNQ2 channel
  opener, STXBP1 gene therapy) and several were terminated, so they belong on
  the gene-level entries where their status can be maintained. `animal_models`
  and `experimental_models` are likewise gene-specific; the one model directly
  used here (the Munc18-1 Ohtahara mouse, PMID:29217410) is cited as
  MODEL_ORGANISM evidence on the synaptic pathophysiology node instead.

  Mortality is not curated as a `phenotypes` entry. HP:0001522 (Death in
  infancy) sits in the HPO Mortality/Aging branch rather than under Phenotypic
  abnormality and is therefore outside the PhenotypeTerm dynamic enum, matching
  the handling in Isolated_Sulfite_Oxidase_Deficiency and
  Microcephalic_Osteodysplastic_Primordial_Dwarfism_Type_I. Mortality is instead
  recorded under `clinical_burden`, where the population-based figure (16% of
  all severe infantile epilepsies dead before age two) is quoted with evidence.
  The EIDEE-specific 14% mortality over a mean 30-month follow-up comes from the
  full text of PMID:38074073 rather than its cached abstract, so it is stated
  there as unquoted free text only.

  Other full-text-derived figures. Several percentages in this entry come from
  the full text of PMID:38074073 and are therefore stated in `description`,
  `rationale` and `notes` fields rather than as evidence snippets: 60%
  drug-resistant and 71% severe developmental delay at follow-up, and the
  interictal EEG breakdown of 42% burst-suppression, 30% multifocal discharges
  and 13% hypsarrhythmia. This follows the repo SOP of moving unquotable claims
  into free text rather than fabricating a snippet.
references:
- reference: PMID:20437616
  title: KCNQ2-Related Disorders.
  tags:
  - GeneReviews
- reference: PMID:27905812
  title: STXBP1 Encephalopathy with Epilepsy.
  tags:
  - GeneReviews
- reference: PMID:38603524
  title: CDKL5 Deficiency Disorder.
  tags:
  - GeneReviews
- reference: PMID:27559564
  title: SCN8A-Related Epilepsy and/or Neurodevelopmental Disorders.
  tags:
  - GeneReviews
- reference: PMID:35503712
  title: "ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions."
- reference: PMID:38074073
  title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
- reference: PMID:39237642
  title: Developmental and epileptic encephalopathies.
prevalence:
- population: Scotland (prospective population-based birth cohort, 169,500 live births)
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 10.0
  rate_low: 5.8
  rate_high: 16.0
  notes: >-
    Cumulative incidence per 100,000 live births for EIDEE explicitly defined to
    include Ohtahara syndrome and early myoclonic encephalopathy, from a
    three-year prospective population-based Scottish study tabulated in the 2024
    Nature Reviews Disease Primers on the DEEs. Recorded as BIRTH_PREVALENCE
    because the denominator is live births in a defined birth cohort rather than
    person-years at risk. The point estimate of 10/100,000 sits exactly on the
    boundary between the Orphanet 1-9/100,000 and 1-5/10,000 bands and the 95%
    CI (5.8-16) straddles both; the higher band is recorded for the point
    estimate, but the true band is uncertain.
  evidence:
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Early Infantile Developmental and Epileptic Encephalopathy (including
      Ohtahara syndrome and Early myoclonic encephalopathy) 10 (5.8-16)
      Prospective population-based, 3 years Scotland; 169,500 live births
    explanation: >-
      Table 1 of the DEE Primer gives the EIDEE cumulative incidence per 100,000
      live births, and its parenthetical makes the Ohtahara/EME subsumption
      explicit in the same row.
- population: Victoria, Australia (population-based cohort of severe epilepsies with onset before 18 months)
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 3.6
  notes: >-
    Incidence of "early infantile epileptic encephalopathy" (the pre-2022 label
    for the same electroclinical concept) in a population-based Victorian
    cohort, reported per 100,000 live births per year alongside West syndrome
    and EIMFS. Lower than the Scottish estimate, consistent with the narrower
    pre-ILAE-2022 EIEE definition and with differences in ascertainment.
  evidence:
  - reference: PMID:33475165
    reference_title: "The severe epilepsy syndromes of infancy: A population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence of epilepsy of infancy with migrating focal seizures (EIMFS)
      was 4.5/100 000 and of early infantile epileptic encephalopathy (EIEE) was
      3.6/100 000.
    explanation: >-
      Provides a second, independent population-based incidence estimate for the
      syndrome under its pre-2022 name.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    In a prospective EIDEE cohort, 60% remained drug-resistant, 71% had severe
    developmental delay or intellectual disability, and 14% died over a mean
    30-month follow-up. In a population-based cohort, every infant with EIEE had
    severe-to-profound developmental delay or was deceased by age two.
  evidence:
  - reference: PMID:33475165
    reference_title: "The severe epilepsy syndromes of infancy: A population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All infants with EIEE or EIMFS had severe-profound delay or were deceased,
      but only 19 of 64 (30%) infants with WS, "WS-like," or "unifocal epilepsy"
      had severe-profound delay
    explanation: >-
      Directly contrasts the uniformly severe outcome of EIEE with the more
      variable outcome of the later-onset infantile syndromes.
  - reference: PMID:33475165
    reference_title: "The severe epilepsy syndromes of infancy: A population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eighteen (16%) infants died before age 2 years.
    explanation: >-
      Population-based mortality figure for the severe infantile epilepsies as a
      group, of which EIEE/EIDEE is among the worst-outcome subgroups.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    The majority of genetically resolved EIDEE is caused by heterozygous de novo
    variants in dominant channel and synaptic genes (KCNQ2, STXBP1, SCN2A,
    SCN8A, GNAO1, KCNT1). Two thirds of pathogenic findings in a prospective
    EIDEE cohort followed dominant inheritance.
  evidence:
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      LOF de novo KCNQ2 variants cause neonatal-onset EIDEE
    explanation: >-
      Illustrates the de novo dominant mechanism for the prototypical EIDEE
      gene. The same sentence continues that inherited KCNQ2 variants instead
      cause self-limited seizures; the snippet is truncated because the source
      PDF carries a reference marker immediately after "EIDEE".
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    A minority of EIDEE is autosomal recessive, most notably the metabolic and
    mitochondrial causes (SLC25A22, biotinidase deficiency, ALDH7A1, PNPO).
    Recessive causes are enriched in consanguineous populations. One third of
    pathogenic findings in a prospective EIDEE cohort were recessive.
  evidence:
  - reference: PMID:19780765
    reference_title: Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we describe a novel SLC25A22 mutation in an unrelated patient born from
      first cousin Algerian parents and presenting severe epileptic
      encephalopathy characterized by an EEG with SB, hypotonia, microcephaly
    explanation: >-
      A homozygous SLC25A22 variant in a consanguineous family is the archetypal
      recessive, metabolic cause of neonatal EE with suppression-burst.
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  description: >-
    CDKL5 and ARX are X-linked causes of EIDEE. ARX mutations act through
    disrupted GABAergic interneuron migration and maturation, producing X-linked
    infantile spasms syndrome and, at the severe end, early-infantile
    encephalopathy with suppression-burst.
  evidence:
  - reference: PMID:22565167
    reference_title: "Interneuron, interrupted: molecular pathogenesis of ARX mutations and X-linked infantile spasms."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      A spectrum of mutations in the Aristaless-Related Homeobox gene (ARX) has
      been linked to ISSX, and downstream targets of this interneuron-expressed
      transcription factor are being defined.
    explanation: >-
      Establishes ARX as an interneuron-expressed transcription factor whose
      mutation spectrum underlies X-linked infantile spasms syndrome (ISSX).
      Marked PARTIAL rather than SUPPORT because the snippet itself names
      neither the X-linked mode of inheritance in words nor EIDEE; the X-linkage
      and the EIDEE-severity end of the ARX spectrum are stated in the body of
      the source rather than in this sentence. Evidence source is OTHER because
      this is a review article.
pathophysiology:
- name: Etiologic Lesion of the Immature Brain
  biological_scale: MOLECULAR
  role: trigger
  description: >-
    EIDEE is a final common electroclinical phenotype rather than a single
    disease, and the upstream lesion is heterogeneous: a pathogenic variant in
    an ion-channel, synaptic, transcriptional or metabolic gene; a structural
    malformation of cortical development or acquired perinatal brain injury; or
    an inborn error of metabolism, frequently a vitamin-responsive one. In a
    prospective EIDEE cohort an etiology was established in 83% of infants -
    genetic in 50%, structural in 19% and metabolic in 14%, with all metabolic
    cases vitamin-responsive.
  notes: >-
    On biological_scale. This node is tagged MOLECULAR because the genetic and
    metabolic etiologies that account for the substantial majority of EIDEE
    (50% + 14% = 64% of the prospective cohort, versus 19% structural) are
    molecular lesions. The structural arm - malformation of cortical development
    and acquired perinatal injury - is genuinely TISSUE-scale, so the single
    tag under-describes that minority. This is a deliberate and disclosed
    compromise, not an oversight: EIDEE is defined by the ILAE as an
    etiologically heterogeneous final common electroclinical phenotype, so a
    single heterogeneous entry-point node is the correct model for it, and
    splitting the node by scale would fragment that construct without adding
    mechanism. Revisit if the structural arm is ever elaborated into its own
    chain.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Regulation of Membrane Potential
    term:
      id: GO:0042391
      label: regulation of membrane potential
    modifier: ABNORMAL
  - preferred_term: Chemical Synaptic Transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: ABNORMAL
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients were further classified into four aetiological groups: genetic
      (50%), structural (19%), metabolic (14%; all were vitamin responsive) and
      unknown
    explanation: >-
      Quantifies the etiologic heterogeneity of the trigger node in the largest
      prospective EIDEE-specific cohort.
  - reference: PMID:35503712
    reference_title: "ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The principal aim of this proposal, consistent with the 2017 ILAE
      Classification of the Epilepsies, is to support epilepsy diagnosis and
      emphasize the importance of classifying epilepsy in an individual both by
      syndrome and etiology.
    explanation: >-
      The ILAE position statement establishes that syndrome and etiology are
      orthogonal axes, which is exactly why EIDEE has a single conserved
      mechanism chain with a heterogeneous trigger. Evidence source is OTHER
      because this is a consensus position statement rather than primary data.
  downstream:
  - target: Reduced Kv7.2/Kv7.3 M-Current
  - target: Increased Persistent Sodium Current
  - target: Impaired Synaptic Vesicle Release and Inhibitory Circuit Formation
  - target: Excitation-Inhibition Imbalance in Immature Cortical Networks
  - target: Developmental and Epileptic Encephalopathy
    description: >-
      The developmental-encephalopathy arm. The etiologic lesion degrades
      development directly, independently of any seizure, by perturbing
      developmental processes and neural cell function in the immature brain.
      This edge is required for the entry to model EIDEE as a developmental AND
      epileptic encephalopathy; without it the pathograph would assert - against
      the ILAE construct and against this entry's own outcome-node description -
      that all developmental impairment is seizure-mediated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39237642
      reference_title: Developmental and epileptic encephalopathies.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        a shared consequence is impairment of higher cortical functions, in
        addition to drug-resistant seizures
      explanation: >-
        States that the impairment of higher cortical function is a consequence
        of the etiology alongside - not downstream of - the drug-resistant
        seizures, which is the direct developmental arm this edge encodes.
- name: Reduced Kv7.2/Kv7.3 M-Current
  biological_scale: MOLECULAR
  role: mechanism
  description: >-
    KCNQ2 and KCNQ3 form the heterotetrameric M-channel that regulates neuronal
    excitability. De novo loss-of-function KCNQ2 variants reduce the M-current
    that repolarizes neurons after firing, removing a brake on repetitive
    discharge and producing neonatal-onset EIDEE. The same gene's inherited
    variants instead cause self-limited familial neonatal epilepsy, so the
    lesion is dose- and mechanism-dependent rather than gene-dependent. This
    node is deliberately separated from the sodium-channel gain-of-function node
    below: the two are opposite-direction lesions converging on the same
    downstream imbalance, and only one of them is a sodium-channel-blocker
    target.
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Potassium Ion Transmembrane Transport
    term:
      id: GO:0071805
      label: potassium ion transmembrane transport
    modifier: DECREASED
  molecular_functions:
  - preferred_term: voltage-gated potassium channel activity
    term:
      id: GO:0005249
      label: voltage-gated potassium channel activity
    modifier: DECREASED
  evidence:
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      LOF de novo KCNQ2 variants cause neonatal-onset EIDEE
    explanation: >-
      States the loss-of-function KCNQ2 to EIDEE relationship directly, using
      the EIDEE label. Evidence source is OTHER because the source is a Nature
      Reviews Disease Primers review article.
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      KCNQ3 and KCNQ2 form the heterotetrameric M-
    explanation: >-
      Identifies the Kv7.2/Kv7.3 heterotetrameric M-channel as the molecular
      substrate. The quote is truncated at "M-" because the source PDF
      hyphenates "M-channel" across a line break. Evidence source is OTHER
      because the source is a review article.
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      KCNQ2 EIDEE typically causes severe to profound impairment
    explanation: >-
      Establishes the clinical severity of the KCNQ2 arm. Marked PARTIAL because
      it speaks to outcome rather than to the M-current mechanism this node
      asserts. Evidence source is OTHER because the source is a review article.
  downstream:
  - target: Excitation-Inhibition Imbalance in Immature Cortical Networks
- name: Increased Persistent Sodium Current
  biological_scale: MOLECULAR
  role: mechanism
  description: >-
    Gain-of-function variants in the sodium-channel alpha subunits SCN2A, SCN8A,
    SCN3A and rarely SCN1A slow fast inactivation, accelerate its recovery, or
    increase persistent inward sodium current, raising intrinsic neuronal
    excitability. This is the arm of the EIDEE channelopathy spectrum that
    responds to sodium-channel-blocker therapy, and it is why the functional
    direction of a sodium-channel variant - not the gene name - determines the
    prescription.
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Sodium Ion Transmembrane Transport
    term:
      id: GO:0035725
      label: sodium ion transmembrane transport
    modifier: INCREASED
  molecular_functions:
  - preferred_term: voltage-gated sodium channel activity
    term:
      id: GO:0005248
      label: voltage-gated sodium channel activity
    modifier: INCREASED
  evidence:
  - reference: PMID:28379373
    reference_title: Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mutations associated with early infantile epilepsy result in increased
      sodium channel activity with gain-of-function, characterized by slowing of
      fast inactivation, acceleration of its recovery or increased persistent
      sodium current
    explanation: >-
      Establishes the gain-of-function biophysical signature specific to SCN2A
      variants presenting with epilepsy onset before three months.
  - reference: PMID:32090326
    reference_title: Biological concepts in human sodium channel epilepsies and their relevance in clinical practice.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with gain-of-function SCN2A/3A/8A missense variants or CNV
      duplications share similar characteristics, most frequently present with
      early onset epilepsy (<3 months)
    explanation: >-
      Extends the gain-of-function-to-early-onset relationship across SCN2A,
      SCN3A and SCN8A as a class.
  downstream:
  - target: Excitation-Inhibition Imbalance in Immature Cortical Networks
- name: Impaired Synaptic Vesicle Release and Inhibitory Circuit Formation
  biological_scale: CELLULAR
  role: mechanism
  description: >-
    The second major genetic class is the synaptopathies and
    interneuronopathies. STXBP1 (Munc18-1) haploinsufficiency disrupts
    SNARE-mediated synaptic vesicle docking and fusion, reducing evoked
    neurotransmitter release; STXBP1 was the single commonest gene in both a
    prospective EIDEE cohort and a burst-suppression cohort. ARX loss disrupts
    the specification and tangential migration of cortical GABAergic
    interneurons, so the inhibitory circuitry itself is built wrong. Recessive
    SLC25A22 loss abolishes mitochondrial glutamate carrier activity, coupling a
    metabolic lesion to the same neurotransmission endpoint.
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  cell_types:
  - preferred_term: GABAergic interneuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  - preferred_term: Glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  biological_processes:
  - preferred_term: Synaptic Vesicle Exocytosis
    term:
      id: GO:0016079
      label: synaptic vesicle exocytosis
    modifier: DECREASED
  - preferred_term: Neuron Migration
    term:
      id: GO:0001764
      label: neuron migration
    modifier: ABNORMAL
  - preferred_term: Glutamate Secretion
    term:
      id: GO:0014047
      label: glutamate secretion
    modifier: ABNORMAL
  evidence:
  - reference: PMID:29217410
    reference_title: Munc18-1 haploinsufficiency impairs learning and memory by reduced synaptic vesicular release in a model of Ohtahara syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Munc18-1 haploinsufficiency impairs learning and memory by reduced
      synaptic vesicular release in a model of Ohtahara syndrome
    explanation: >-
      A mouse model of STXBP1/Munc18-1 haploinsufficiency, explicitly framed as
      an Ohtahara syndrome model, links the genetic lesion to reduced synaptic
      vesicular release. Evidence source is MODEL_ORGANISM; this mechanism is
      not directly demonstrated in human brain tissue.
  - reference: PMID:32247221
    reference_title: Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with the most commonly diagnosed gene being STXBP1 (n = 13, 27.1 %),
      followed by KCNQ2 (n = 5, 10.4 %), SCN2A (n = 5, 10.4 %)
    explanation: >-
      Shows the synaptic gene STXBP1 is the single commonest molecular diagnosis
      in early-onset epileptic encephalopathy with burst suppression, ahead of
      the channel genes.
  - reference: PMID:19780765
    reference_title: Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We showed that this patient carried a homozygous p.G236W SLC25A22 mutation
      which alters a highly conserved amino acid and completely abolishes the
      glutamate carrier's activity in vitro.
    explanation: >-
      Ties a recessive metabolic lesion (mitochondrial glutamate carrier loss)
      to the same neurotransmission endpoint in neonatal EE with
      suppression-burst.
  downstream:
  - target: Excitation-Inhibition Imbalance in Immature Cortical Networks
- name: Excitation-Inhibition Imbalance in Immature Cortical Networks
  biological_scale: CELLULAR
  role: amplifier
  description: >-
    Whatever the upstream lesion, the convergent consequence is a shift of the
    balance between glutamatergic excitation and GABAergic inhibition toward net
    excitation, occurring in cortical networks that are still being assembled.
    The immature-brain context matters: the same lesion acting later produces a
    different, usually milder, syndrome, and the age factor is the common
    denominator that determines whether the resulting electroclinical picture is
    EIDEE, infantile epileptic spasms syndrome, or Lennox-Gastaut syndrome.
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: GABA Signaling Pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutual transition suggests the same pathophysiology among three syndromes
      and the age factor should be considered as the common denominator
      responsible for the manifestation of each of their own specific
      clinico-electrical features.
    explanation: >-
      Ohtahara's own case series argues that the same underlying
      pathophysiology, filtered through developmental age, yields EIDEE, West
      syndrome or Lennox-Gastaut syndrome - the rationale for the
      developmental-context half of this node. Marked PARTIAL because it does
      not address the excitation/inhibition claim itself.
  - reference: PMID:30764523
    reference_title: "Pediatric Epilepsy Mechanisms: Expanding the Paradigm of Excitation/Inhibition Imbalance."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Those considerations gave rise to the excitation/inhibition (E/I)
      imbalance theory, whereby increased excitation, decreased inhibition, or
      both favor a hyperexcitable state and an increased propensity for seizure
      generation and epileptogenesis.
    explanation: >-
      Defines the E/I imbalance paradigm asserted by this node, in a
      paediatric-epilepsy-specific source. This is the same evidence the
      epilepsy_excitation_inhibition_imbalance module uses for the node this one
      conforms to. Evidence source is OTHER because this is a review article.
  - reference: PMID:33808762
    reference_title: "The Role of Phospholipase C in GABAergic Inhibition and Its Relevance to Epilepsy."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      In the brain, GABA is a major inhibitory neurotransmitter and plays a
      pivotal role in maintaining E/I balance.
    explanation: >-
      Supports the GABAergic arm of the imbalance. Marked PARTIAL because the
      source is about autism spectrum disorders rather than EIDEE; it is used
      only for the general neurotransmitter claim, matching its use in the
      epilepsy module. Evidence source is OTHER because this is a review article.
  downstream:
  - target: Burst-Suppression and Hypersynchronous Cortical Discharge
- name: Burst-Suppression and Hypersynchronous Cortical Discharge
  biological_scale: TISSUE
  role: central_effector
  description: >-
    Net excitatory bias in the immature cortex produces hypersynchronous
    population discharge whose electrographic expression in EIDEE is
    characteristically a suppression-burst pattern: bursts of 1-3 seconds of
    high-voltage activity alternating with a nearly flat suppression phase of
    2-5 seconds, present regardless of the circadian cycle. Tonic spasms occur
    concomitantly with the bursts. Burst-suppression is characteristic but not
    obligatory - in a prospective EIDEE cohort it was present in 42%, with
    multifocal discharges in 30% and hypsarrhythmia in 13%.
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Regulation of Membrane Potential
    term:
      id: GO:0042391
      label: regulation of membrane potential
    modifier: ABNORMAL
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bursts of 1-3s duration alternate with nearly flat suppression phase of
      2-5s at an approximately regular rate; 5-10s of burst-burst interval.
    explanation: >-
      Gives the quantitative electrographic definition of the suppression-burst
      pattern that is the signature effector readout of this node.
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tonic spasms appear concomitant with bursts.
    explanation: >-
      Couples the clinical seizure to the electrographic burst, establishing
      that the burst is the hypersynchronous discharge event.
  downstream:
  - target: Recurrent Drug-Resistant Seizures
- name: Recurrent Drug-Resistant Seizures
  biological_scale: ORGANISM
  role: outcome
  description: >-
    Hypersynchronous discharge is expressed clinically as frequent, recurrent,
    unprovoked seizures - multiple daily in most infants - that are typically
    refractory to multiple antiseizure medications in combination. This is the
    epilepsy proper, and it is separable from the encephalopathy that follows
    it: seizures remit in some genotypes without developmental recovery.
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  evidence:
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the
      first week of life that are mostly tonic, with associated focal motor and
      autonomic features.
    explanation: >-
      Documents recurrent multiple-daily seizures as the clinical expression in
      the prototypical genetic EIDEE.
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizures may be resistant to multiple ASMs alone or in combination.
    explanation: >-
      Documents the drug-resistant character of the recurrent seizures.
  downstream:
  - target: Developmental and Epileptic Encephalopathy
    description: >-
      The epileptic-encephalopathy arm: the additive, in-principle-modifiable
      contribution of the epileptiform activity itself to the developmental
      outcome, over and above the direct developmental arm.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - eidee_epileptic_component_reversibility
- name: Developmental and Epileptic Encephalopathy
  biological_scale: ORGANISM
  role: outcome
  description: >-
    The clinical endpoint is a two-component encephalopathy. A developmental
    encephalopathy arises directly from the etiology and impairs development
    independently of any seizure; an epileptic encephalopathy is superimposed
    when the epileptiform activity itself further degrades cognition and
    behaviour beyond what the underlying pathology alone would produce. The
    distinguishing feature of EIDEE specifically is that these two components
    cannot be separated: onset at or before three months means the etiology and
    the epileptiform activity act on the same window of development. This is the
    mechanistic reason EIDEE is defined as a developmental AND epileptic
    encephalopathy rather than a pure epileptic encephalopathy, and the reason
    seizure control alone does not restore development.

    Module note: this node declares no conforms_to. The
    epilepsy_excitation_inhibition_imbalance module terminates at recurrent
    unprovoked seizures (conformed above by Recurrent Drug-Resistant Seizures);
    the two-component developmental-plus-epileptic encephalopathy is
    EIDEE-specific content that lies beyond the module's chain. The module's
    "Seizure Generation and Epileptogenesis" node is likewise not separately
    instantiated: in EIDEE the epileptogenesis step is not clinically separable
    from the burst-suppression effector that precedes it, so splitting it out
    would create a node with no independent evidence.
  biological_processes:
  - preferred_term: Nervous System Development
    term:
      id: GO:0007399
      label: nervous system development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      developmental impairment and an EE, such as EIDEE, including Ohtahara
      syndrome and Early Myoclonic Encephalopathy
    explanation: >-
      The DEE Primer states that separating the developmental from the epileptic
      encephalopathy is often impossible in an infant under three months who
      presents with developmental impairment and an epileptic encephalopathy
      such as EIDEE - and, in the same clause, names Ohtahara syndrome and early
      myoclonic encephalopathy as instances of EIDEE.
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      beyond what might be expected from the underlying pathology alone, and
      that these can worsen over time
    explanation: >-
      The closing clause of the ILAE definition of an epileptic encephalopathy -
      that the epileptic activity itself contributes to impairment beyond what
      the underlying pathology alone would produce, and that this can worsen
      over time. This is the epileptic component superimposed on the
      developmental encephalopathy in this node.
mechanistic_hypotheses:
- hypothesis_group_id: eidee_epileptic_component_reversibility
  hypothesis_label: >-
    Suppressing epileptiform activity in EIDEE recovers a separable share of
    developmental potential
  status: EMERGING
  description: >-
    The DEE construct implies that the epileptic component of the encephalopathy
    is, in principle, modifiable: if the epileptiform activity independently
    degrades development, then abolishing it should yield developmental gains
    over and above the fixed developmental encephalopathy. There are clear
    proofs of principle in other DEEs (withdrawal of contraindicated
    sodium-channel blockers in Dravet syndrome, EEG normalization in
    Landau-Kleffner syndrome). Whether this holds for EIDEE specifically is
    unresolved, because at onset before three months the two components act on
    the same developmental window and cannot be dissociated clinically. In
    KCNQ2-EIDEE, for example, seizures remit in more than half of patients in
    early life yet impairment remains severe to profound - which argues that the
    developmental component dominates in at least some genotypes.
  evidence:
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      there are clear examples where improvement of seizure control or
      resolution of interictal EEG abnormalities ameliorate cognitive outcome
    explanation: >-
      Supports the general premise for the DEEs while the same source notes it
      is difficult to determine any additive effect of seizures on cognitive
      outcome, which is why this is recorded as an emerging hypothesis rather
      than an established mechanism.
phenotypes:
- category: Neurological
  name: Seizure Onset at or Before Three Months of Age
  frequency: OBLIGATE
  description: >-
    Seizure onset at or before three months of age is the defining, mandatory
    feature that separates EIDEE from the later-onset infantile syndromes. In a
    prospective EIDEE cohort the median age at seizure onset was 28 days with a
    range of 1-90 days, and most infants presented in the neonatal period.
  diagnostic: true
  phenotype_term:
    preferred_term: Neonatal seizure
    term:
      id: HP:0032807
      label: Neonatal seizure
  evidence:
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the
      first week of life
    explanation: >-
      Documents neonatal seizure onset in the prototypical genetic EIDEE.
      Frequency is OBLIGATE because onset at or before three months is part of
      the syndrome definition rather than an observed proportion.
- category: Neurological
  name: Tonic Seizures and Tonic Spasms
  frequency: FREQUENT
  description: >-
    Frequent tonic seizures and tonic spasms, occurring both awake and asleep
    and often in clusters, are the classic seizure type of the Ohtahara arm of
    EIDEE. Tonic spasms appear concomitantly with the EEG bursts. In a
    prospective EIDEE cohort, tonic seizures were significantly less likely in
    the vitamin-responsive and structural etiologic groups than in the
    genetic/unknown groups.
  phenotype_term:
    preferred_term: Tonic seizure
    term:
      id: HP:0032792
      label: Tonic seizure
  evidence:
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ohtahara syndrome (OS) is characterized by frequent tonic spasms, with or
      without clustering, of early onset within a few months of life, and a
      suppression-burst (S-B) pattern in electroencephalography (EEG). Tonic
      spasms occur in not only waking but also sleeping state in most cases.
    explanation: >-
      Defines frequent tonic spasms as a core feature occurring in most cases,
      supporting the FREQUENT band.
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      vitamin responsive/structural aetiology patients were less likely to have
      tonic seizures (Risk Ratio = 0.66; P = 0.04)
    explanation: >-
      Shows tonic seizures are etiology-dependent within EIDEE; marked PARTIAL
      because it quantifies a between-group contrast rather than the overall
      frequency.
- category: Neurological
  name: Myoclonic Seizures
  description: >-
    Erratic, fragmentary or massive myoclonus was the defining seizure type of
    early myoclonic encephalopathy, the arm of EIDEE historically associated
    with inborn errors of metabolism. Myoclonic seizures remain one of the
    common seizure types recorded in EIDEE cohorts alongside clonic and tonic
    seizures. No frequency band is assigned: published EIDEE cohorts report
    seizure-type lists without a myoclonus-specific proportion.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
  evidence:
  - reference: PMID:23044011
    reference_title: "Early-onset epileptic encephalopathies: Ohtahara syndrome and early myoclonic encephalopathy."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      Ohtahara syndrome and early myoclonic encephalopathy are the earliest
      presenting of the epileptic encephalopathies.
    explanation: >-
      Establishes early myoclonic encephalopathy as one of the two constituent
      presentations now unified as EIDEE. Marked PARTIAL because the snippet
      names the syndrome but does not itself describe myoclonus; the link from
      "early myoclonic encephalopathy" to myoclonic seizures as its defining
      seizure type is definitional rather than quoted. Evidence source is OTHER
      because this is a review article.
  - reference: PMID:27905812
    reference_title: STXBP1 Encephalopathy with Epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure types can include infantile spasms; generalized tonic-clonic,
      clonic, or tonic seizures; and myoclonic, atonic, absence, and focal
      seizures.
    explanation: >-
      GeneReviews for the commonest EIDEE gene lists myoclonic seizures among
      the seizure types seen, which is the direct evidence that myoclonus occurs
      in EIDEE rather than only in the historical EME label.
- category: Neurological
  name: Focal Clonic Seizures
  description: >-
    Focal clonic seizures are one of the common seizure types in EIDEE and, in a
    prospective cohort, were significantly more common in the vitamin-responsive
    and structural etiologic groups than in the genetic and unknown groups.
    Partial (focal) seizures were observed in about one third of the original
    Ohtahara series. No frequency band is assigned because the sources report a
    between-group risk ratio and a historical proportion rather than a
    syndrome-wide frequency.
  phenotype_term:
    preferred_term: Focal clonic seizure
    term:
      id: HP:0002266
      label: Focal clonic seizure
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clonic seizures were more common in the vitamin responsive/structural
      groups (Risk Ratio = 1.36; P = 0.05) as compared to patients with
      'genetic/unknown' aetiologies.
    explanation: >-
      Documents clonic seizures as a common EIDEE seizure type with an
      etiology-dependent distribution.
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Partial seizures are observed in about one-third of cases.
    explanation: >-
      Historical proportion of focal seizures in the original Ohtahara series.
      Marked PARTIAL because the source says "partial" (focal) without
      specifying a clonic semiology, so it supports the focal component of this
      phenotype but not the clonic component.
- category: Neurological
  name: Burst-Suppression EEG
  frequency: FREQUENT
  description: >-
    A persistent interictal suppression-burst pattern - high-voltage bursts of
    1-3 seconds alternating with a nearly flat suppression phase of 2-5 seconds,
    unchanged across the sleep-wake cycle - is the classic EEG signature of
    EIDEE and was the defining feature of both Ohtahara syndrome and early
    myoclonic encephalopathy. It is characteristic but not obligatory: in a
    prospective EIDEE cohort burst-suppression was seen in 42%, multifocal
    discharges in 30% and hypsarrhythmia in 13%.
  diagnostic: true
  phenotype_term:
    preferred_term: EEG with burst suppression
    term:
      id: HP:0010851
      label: EEG with burst suppression
  evidence:
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      S-B pattern is persistently observed regardless of circadian cycle.
    explanation: >-
      Records the persistence of the suppression-burst pattern across the
      circadian cycle, the feature that distinguishes it from transient
      burst-suppression seen in other contexts.
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At onset, EEG shows a burst-suppression pattern or multifocal epileptiform
      activity
    explanation: >-
      GeneReviews confirms that burst-suppression is one of two alternative
      onset EEG patterns in the prototypical genetic EIDEE, supporting FREQUENT
      rather than OBLIGATE.
- category: Neurological
  name: Hypsarrhythmia
  description: >-
    Hypsarrhythmia may be the presenting interictal EEG pattern in a minority of
    EIDEE infants, and is the pattern into which suppression-burst
    characteristically evolves at around age 3-6 months as EIDEE transitions to
    infantile epileptic spasms syndrome. No frequency band is assigned because
    the available proportion (13%) comes from a single referral cohort.
  phenotype_term:
    preferred_term: Hypsarrhythmia
    term:
      id: HP:0002521
      label: Hypsarrhythmia
  evidence:
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      proceed concomitantly with EEG transition from S-B to hypsarrhythmia at
      around age 3-6 months
    explanation: >-
      Documents the suppression-burst to hypsarrhythmia transition that
      accompanies evolution to West syndrome.
  - reference: PMID:27905812
    reference_title: STXBP1 Encephalopathy with Epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EEG abnormalities can include focal epileptic activity, burst suppression,
      hypsarrhythmia, or generalized spike-and-slow waves.
    explanation: >-
      GeneReviews for the commonest EIDEE gene lists hypsarrhythmia as one of
      the alternative interictal EEG patterns.
- category: Neurological
  name: Drug-Resistant Epilepsy
  frequency: FREQUENT
  description: >-
    Seizures in EIDEE are typically refractory to multiple antiseizure
    medications. In a prospective EIDEE cohort, 60% remained drug-resistant at a
    mean 30-month follow-up, and only vitamin-responsive etiology was an
    independently significant predictor of seizure control.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      only vitamin responsive aetiology had a statistically significant positive
      effect on seizure control (P = 0.02)
    explanation: >-
      Shows that outside the vitamin-responsive subgroup no factor predicted
      seizure control, i.e. drug resistance is the norm.
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizures may be resistant to multiple ASMs alone or in combination.
    explanation: >-
      GeneReviews confirms multidrug resistance in the prototypical genetic
      EIDEE.
- category: Neurological
  name: Severe to Profound Developmental Delay and Intellectual Disability
  frequency: VERY_FREQUENT
  description: >-
    Severe to profound developmental impairment is near-universal. In a
    prospective EIDEE cohort 71% had severe developmental delay or intellectual
    disability at follow-up, and in a population-based cohort every surviving
    infant with EIEE had severe-to-profound delay. Infants in the
    genetic/unknown etiologic groups had markedly higher odds of severe delay
    (OR 57) than those with vitamin-responsive or structural causes.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
    severity: SEVERE
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in the 'genetic/unknown' groups were more frequently observed to have
      severe developmental delay (Odds Ratio = 57; P < 0.0001)
    explanation: >-
      Quantifies severe developmental delay and its dependence on etiologic
      group.
  - reference: PMID:33475165
    reference_title: "The severe epilepsy syndromes of infancy: A population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All infants with EIEE or EIMFS had severe-profound delay or were deceased
    explanation: >-
      Population-based confirmation that severe-to-profound impairment is the
      rule, supporting VERY_FREQUENT.
- category: Neurological
  name: Abnormal Neurological Examination with Hypotonia
  description: >-
    An abnormal neurological examination is part of the EIDEE syndrome
    definition. Axial hypotonia, often with limb hypertonia or later spasticity,
    is the usual finding. Tone abnormalities were significantly more common in
    the genetic/unknown etiologic groups (OR 9). No frequency band is assigned
    for hypotonia specifically because the cohort reports an odds ratio for
    tone abnormalities as a class rather than a hypotonia proportion.
  diagnostic: true
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      tone abnormalities (Odds Ratio = 9; P = 0.0006)
    explanation: >-
      Quantifies tone abnormality as a discriminating feature of the
      genetic/unknown EIDEE groups. Marked PARTIAL because the cohort reports
      tone abnormalities as a class, not hypotonia specifically.
  - reference: PMID:19780765
    reference_title: Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presenting severe epileptic encephalopathy characterized by an EEG with
      SB, hypotonia, microcephaly and abnormal electroretinogram
    explanation: >-
      Documents hypotonia as part of the neonatal EE with suppression-burst
      phenotype.
- category: Neurological
  name: Movement Disorder
  description: >-
    Dystonia, dyskinesia, choreoathetosis and other movement disorders are a
    recognized comorbidity, particularly in the SNAREopathy (STXBP1, SNAP25,
    VAMP2, DNM1, CPLX1) and GNAO1 causes. Movement disorder was significantly
    enriched in the genetic/unknown etiologic groups (OR 19). No frequency band
    is assigned: the available statistic is a between-group odds ratio.
  phenotype_term:
    preferred_term: Movement disorder (dystonia, dyskinesia, choreoathetosis)
    term:
      id: HP:0100022
      label: Abnormality of movement
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      movement disorder (Odds Ratio = 19; P < 0.0001)
    explanation: >-
      Quantifies movement disorder as a discriminating feature of genetic EIDEE.
      Marked PARTIAL because the source reports movement disorder as a class,
      not dystonia specifically.
  - reference: PMID:27905812
    reference_title: STXBP1 Encephalopathy with Epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other neurologic findings include abnormal tone, movement disorders
      (especially ataxia and dystonia), and behavioral issues and autism
      spectrum disorder.
    explanation: >-
      GeneReviews for the commonest EIDEE gene lists dystonia and other movement
      disorders among the core neurological findings.
- category: Behavioral
  name: Autistic Behaviour
  description: >-
    Autistic behaviours are a recognized outcome in survivors, strongly
    associated with genetic and unknown etiologies (OR 37) rather than
    vitamin-responsive or structural causes. No frequency band is assigned: the
    available statistic is a between-group odds ratio.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      autistic behaviours (Odds Ratio = 37; P < 0.0001)
    explanation: >-
      Quantifies autistic behaviour as a discriminating outcome of the
      genetic/unknown EIDEE groups. Marked PARTIAL because the source reports a
      between-group odds ratio rather than a syndrome-wide frequency.
  - reference: PMID:27905812
    reference_title: STXBP1 Encephalopathy with Epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      behavioral issues and autism spectrum disorder
    explanation: >-
      GeneReviews lists autism spectrum disorder among the neurological and
      behavioural findings in the commonest EIDEE gene.
- category: Neurological
  name: Microcephaly
  description: >-
    Acquired postnatal microcephaly reflects the arrest of brain growth that
    accompanies the developmental encephalopathy, and is prominent in the
    metabolic causes such as SLC25A22 deficiency. No frequency band is assigned:
    the supporting evidence is case-level.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:19780765
    reference_title: Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an EEG with SB, hypotonia, microcephaly and abnormal electroretinogram
    explanation: >-
      Documents microcephaly as part of the neonatal EE with suppression-burst
      phenotype in a molecularly confirmed case.
- category: Neuroimaging
  name: Structural Brain Abnormality on MRI
  frequency: FREQUENT
  description: >-
    Brain MRI is abnormal in a substantial minority of EIDEE infants. In a
    prospective cohort MRI was abnormal in 35/80 (44%), of which 16/35 showed a
    malformation of cortical development and 19/35 non-specific changes that did
    not establish an etiology. The original Ohtahara series reported structural
    abnormalities, notably asymmetric lesions, in most cases.
  phenotype_term:
    preferred_term: Structural brain abnormality on MRI
    term:
      id: HP:0012443
      label: Abnormal brain morphology
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MRI was abnormal in 35/80 patients (malformation observed in 16/35; 19/35
      had non-specific changes that did not contribute to underlying aetiology)
    explanation: >-
      Quantifies the frequency and character of structural imaging abnormality
      in EIDEE, supporting a FREQUENT band for any abnormality.
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Brain imagings reveal structural abnormalities including malformations,
      notably asymmetric lesions in most cases.
    explanation: >-
      The original Ohtahara series reports structural abnormality including
      malformation in most cases.
progression:
- phase: Neonatal/early infantile onset
  age_range: birth to 3 months
  notes: >-
    Frequent tonic, clonic or myoclonic seizures begin at or before 3 months,
    with a persistently abnormal interictal EEG (suppression-burst, multifocal
    discharges or hypsarrhythmia) and an abnormal neurological examination.
    Median onset in a prospective cohort was 28 days, range 1-90 days.
  evidence:
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      frequent tonic spasms, with or without clustering, of early onset within a
      few months of life
    explanation: Defines the onset phase of the syndrome.
- phase: Evolution to infantile epileptic spasms syndrome
  age_range: 3 to 6 months
  notes: >-
    Many infants evolve from EIDEE to West syndrome (infantile epileptic spasms
    syndrome), with the EEG transitioning from suppression-burst to
    hypsarrhythmia at around age 3-6 months. This age-dependent transition is
    the historical basis for treating EIDEE, West syndrome and Lennox-Gastaut
    syndrome as a single age-dependent epileptic encephalopathy continuum.
  evidence:
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Characteristic age-dependent evolution from OS to West syndrome (WS) in
      many cases, and further from WS to Lennox-Gastaut syndrome (LGS) in some
    explanation: Documents the syndromic evolution sequence.
- phase: Later childhood - chronic drug-resistant epilepsy with profound impairment
  age_range: 1 year onward
  notes: >-
    Further evolution from West syndrome to Lennox-Gastaut syndrome occurs in
    some, with the EEG moving from hypsarrhythmia to diffuse slow spike-waves at
    around age 1 year. Seizures may remit in some genotypes (over 50% of
    KCNQ2-EIDEE by age 9 months to 4 years) without corresponding developmental
    recovery, leaving moderate-to-profound impairment.
  evidence:
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizures generally cease between ages nine months and four years. At
      onset, EEG shows a burst-suppression pattern or multifocal epileptiform
      activity; early brain MRI can show basal ganglia hyperdensities and later
      MRIs may show white matter or general volume loss.
      Moderate-to-profound developmental impairment is present.
    explanation: >-
      Documents late seizure remission in the prototypical genetic EIDEE
      alongside the persisting moderate-to-profound developmental impairment.
genetic:
- name: STXBP1
  gene_term:
    preferred_term: STXBP1
    term:
      id: hgnc:11444
      label: STXBP1
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Autosomal dominant, typically de novo. Curated in detail in the dismech
    entry STXBP1_Encephalopathy. Munc18-1 haploinsufficiency disrupting
    SNARE-mediated synaptic vesicle release.
  case_fractions:
  - population: Korean early-onset epileptic encephalopathy with burst suppression cohort
    case_fraction_percent: 27.1
    cohort_size: 48
    notes: >-
      Commonest single-gene diagnosis in a cohort selected on the
      burst-suppression EEG that defines the classic EIDEE phenotype.
    evidence:
    - reference: PMID:32247221
      reference_title: Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        with the most commonly diagnosed gene being STXBP1 (n = 13, 27.1 %)
      explanation: Direct per-gene case fraction in an EOEE-BS cohort.
  evidence:
  - reference: PMID:27905812
    reference_title: STXBP1 Encephalopathy with Epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median age of onset of seizures is six weeks (range: 1 day to 13
      years).
    explanation: >-
      GeneReviews confirms that the modal STXBP1 presentation falls inside the
      EIDEE onset window of three months.
- name: KCNQ2
  gene_term:
    preferred_term: KCNQ2
    term:
      id: hgnc:6296
      label: KCNQ2
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Autosomal dominant, typically de novo. Curated in detail in
    KCNQ2_Developmental_and_Epileptic_Encephalopathy. De novo loss-of-function
    variants reduce the Kv7.2/Kv7.3 M-current and cause neonatal-onset EIDEE,
    whereas inherited variants in the same gene cause self-limited familial
    neonatal epilepsy - the clearest example in EIDEE that variant effect, not
    gene identity, determines the syndrome.
  case_fractions:
  - population: Korean early-onset epileptic encephalopathy with burst suppression cohort
    case_fraction_percent: 10.4
    cohort_size: 48
    evidence:
    - reference: PMID:32247221
      reference_title: Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        followed by KCNQ2 (n = 5, 10.4 %)
      explanation: Direct per-gene case fraction in an EOEE-BS cohort.
  evidence:
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the
      first week of life that are mostly tonic, with associated focal motor and
      autonomic features.
    explanation: >-
      GeneReviews describes the KCNQ2 neonatal-onset DEE phenotype, which falls
      squarely inside EIDEE.
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      LOF de novo KCNQ2 variants cause neonatal-onset EIDEE
    explanation: >-
      States the KCNQ2 loss-of-function to EIDEE relationship explicitly using
      the EIDEE label.
- name: SCN2A
  gene_term:
    preferred_term: SCN2A
    term:
      id: hgnc:10588
      label: SCN2A
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Autosomal dominant, typically de novo. Curated in detail in
    SCN2A-Related_Developmental_and_Epileptic_Encephalopathy. Gain-of-function
    missense variants present with epilepsy before three months and respond to
    sodium-channel blockers; loss-of-function variants present later and do not.
  case_fractions:
  - population: Korean early-onset epileptic encephalopathy with burst suppression cohort
    case_fraction_percent: 10.4
    cohort_size: 48
    evidence:
    - reference: PMID:32247221
      reference_title: Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        SCN2A (n = 5, 10.4 %)
      explanation: Direct per-gene case fraction in an EOEE-BS cohort.
  evidence:
  - reference: PMID:28379373
    reference_title: Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      truncating mutations were exclusively seen in patients with late onset
      epilepsies and lack of response to sodium channel blockers
    explanation: >-
      Establishes the genotype/onset-age/treatment-response correlation that
      makes SCN2A an EIDEE gene only in its gain-of-function form.
- name: SCN8A
  gene_term:
    preferred_term: SCN8A
    term:
      id: hgnc:10596
      label: SCN8A
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Autosomal dominant, typically de novo. Curated in detail in
    SCN8A-Related_Developmental_and_Epileptic_Encephalopathy. Gain-of-function
    variants in Nav1.6 increase neuronal excitability and can present within the
    EIDEE onset window.
  evidence:
  - reference: PMID:27559564
    reference_title: SCN8A-Related Epilepsy and/or Neurodevelopmental Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Epilepsy phenotypes include developmental and epileptic encephalopathy
      (DEE) associated with severe developmental delays and usually
      pharmacoresistant epilepsy with multiple seizure types
    explanation: >-
      GeneReviews establishes the severe, pharmacoresistant DEE end of the SCN8A
      phenotypic spectrum, the arm relevant to EIDEE.
  - reference: PMID:27559564
    reference_title: SCN8A-Related Epilepsy and/or Neurodevelopmental Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypotonia and movement disorders including dystonia, ataxia, and
      choreoathetosis are common in some phenotypes.
    explanation: >-
      GeneReviews documents the hypotonia and movement-disorder comorbidities
      that this entry curates as EIDEE phenotypes.
  - reference: PMID:32090326
    reference_title: Biological concepts in human sodium channel epilepsies and their relevance in clinical practice.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with gain-of-function SCN2A/3A/8A missense variants or CNV
      duplications share similar characteristics, most frequently present with
      early onset epilepsy (<3 months), and demonstrate good response to sodium
      channel blockers (SCBs).
    explanation: >-
      Groups SCN2A, SCN3A and SCN8A gain-of-function variants as a class
      presenting within the EIDEE onset window with a shared treatment response.
- name: CDKL5
  gene_term:
    preferred_term: CDKL5
    term:
      id: hgnc:11411
      label: CDKL5
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    X-linked, typically de novo. Curated in detail in CDKL5_Deficiency_Disorder.
    A recognized cause of severe early-onset DEE; epileptic spasms are a
    prominent seizure type. Whether an individual CDKL5 case meets the EIDEE
    definition turns on whether seizure onset falls at or before three months,
    which is variable within the disorder.
  case_fractions:
  - population: Korean early-onset epileptic encephalopathy with burst suppression cohort
    case_fraction_percent: 2.1
    cohort_size: 48
    evidence:
    - reference: PMID:32247221
      reference_title: Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        CDKL5 (n = 1, 2.1 %)
      explanation: Direct per-gene case fraction in an EOEE-BS cohort.
  evidence:
  - reference: PMID:38603524
    reference_title: CDKL5 Deficiency Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CDKL5 deficiency disorder (CDD) is a developmental and epileptic
      encephalopathy (DEE) characterized by severe early-onset intractable
      epilepsy and motor, cognitive, visual, and autonomic disturbances.
    explanation: >-
      GeneReviews establishes CDKL5 deficiency disorder as a severe early-onset
      developmental and epileptic encephalopathy.
- name: GNAO1
  gene_term:
    preferred_term: GNAO1
    term:
      id: hgnc:4389
      label: GNAO1
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Autosomal dominant, typically de novo. Curated in detail in
    GNAO1-Related_Developmental_and_Epileptic_Encephalopathy. G-protein alpha-o
    subunit; presents with early-onset DEE frequently combined with a severe
    movement disorder.
  case_fractions:
  - population: Korean early-onset epileptic encephalopathy with burst suppression cohort
    case_fraction_percent: 2.1
    cohort_size: 48
    evidence:
    - reference: PMID:32247221
      reference_title: Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        GNAO1 (n = 1, 2.1 %)
      explanation: Direct per-gene case fraction in an EOEE-BS cohort.
  evidence:
  - reference: PMID:39419567
    reference_title: "The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      CDKL5, CSNK2B, GABAAr, GNAO1, GRIN1
    explanation: >-
      Lists GNAO1 among the well-known genes linked to the DEEs. Evidence source
      is OTHER because this is a review article.
- name: KCNT1
  gene_term:
    preferred_term: KCNT1
    term:
      id: hgnc:18865
      label: KCNT1
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Autosomal dominant, typically de novo. Gain-of-function variants increase
    sodium-activated potassium current. Most characteristically causes epilepsy
    of infancy with migrating focal seizures (curated separately as
    Epilepsy_of_Infancy_with_Migrating_Focal_Seizures), but also contributes to
    EIDEE. Quinidine is a mechanistically motivated but inconsistently effective
    precision therapy.
  evidence:
  - reference: PMID:39419567
    reference_title: "The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      KCNQ2, KCNT1, NBEA, PCDH19, SCN1A, SCN2A, SCN8A, STXBP1
    explanation: >-
      Lists KCNT1 among the well-known genes linked to the DEEs. Evidence source
      is OTHER because this is a review article.
- name: SLC25A22
  gene_term:
    preferred_term: SLC25A22
    term:
      id: hgnc:19954
      label: SLC25A22
  relationship_type: CAUSATIVE
  notes: >-
    Autosomal recessive. Mitochondrial glutamate carrier; the archetypal
    recessive metabolic cause of neonatal epileptic encephalopathy with
    suppression-burst, described in consanguineous families.
  evidence:
  - reference: PMID:19780765
    reference_title: Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Comparison of the clinical features of patients from both families
      suggests that SLC25A22 mutations are responsible for a novel clinically
      recognizable epileptic encephalopathy with SB.
    explanation: >-
      Establishes SLC25A22 as a cause of neonatal epileptic encephalopathy with
      suppression-burst.
- name: ARX
  gene_term:
    preferred_term: ARX
    term:
      id: hgnc:18060
      label: ARX
  relationship_type: CAUSATIVE
  notes: >-
    X-linked. Aristaless-related homeobox transcription factor expressed in
    GABAergic interneurons. Mutation causes X-linked infantile spasms syndrome
    and, at the severe end, early-infantile encephalopathy with
    suppression-burst - an interneuronopathy rather than a channelopathy or
    synaptopathy.
  evidence:
  - reference: PMID:22565167
    reference_title: "Interneuron, interrupted: molecular pathogenesis of ARX mutations and X-linked infantile spasms."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      complex interactions between Arx and its binding partners and their
      effects on cell migration and maturation that can help explain the
      diversity of ARX phenotypes
    explanation: >-
      Establishes disrupted interneuron migration and maturation as the ARX
      mechanism. Evidence source is OTHER because this is a review article.
- name: SCN1A
  gene_term:
    preferred_term: SCN1A
    term:
      id: hgnc:10585
      label: SCN1A
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Autosomal dominant, typically de novo. A deliberate boundary case.
    Loss-of-function SCN1A causes Dravet syndrome (curated as Dravet_syndrome),
    which is NOT EIDEE - onset is typically at 5-6 months. Rare gain-of-function
    SCN1A variants instead cause a non-Dravet EIDEE phenotype with onset by
    three months, and carry the opposite sodium-channel-blocker recommendation.
    Assigning an SCN1A case to EIDEE versus Dravet syndrome therefore requires
    the functional direction of the variant, not just the gene name.
  evidence:
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      patients with the non-Dravet, EIDEE phenotype due to GOF variants may
      respond to SCB, such as carbamazepine and phenytoin
    explanation: >-
      States the SCN1A gain-of-function EIDEE phenotype and its opposite
      treatment implication relative to Dravet syndrome.
treatments:
- name: Etiology-Guided Diagnostic Workup and Precision Treatment
  description: >-
    Because EIDEE is defined electroclinically but treated etiologically, the
    single most consequential intervention is rapid etiologic diagnosis: video
    EEG, epilepsy-protocol brain MRI, targeted metabolic testing, and rapid trio
    exome or genome sequencing. Molecular diagnosis was achieved in 69% of
    tested infants in a prospective EIDEE cohort. The diagnosis then determines
    treatment direction - vitamin supplementation, sodium-channel blockade,
    channel opener, resective surgery or ketogenic diet - and the same gene can
    require opposite treatments depending on the functional direction of the
    variant.
  treatment_term:
    preferred_term: Targeted Therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
  therapeutic_modality: OTHER
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A molecular diagnosis was achieved in 53 out of 77 patients tested (69%).
      Next-generation sequencing had a yield of 51%, while microarray had a
      yield of 14%.
    explanation: >-
      Quantifies the diagnostic yield that makes an etiology-first strategy
      worthwhile in EIDEE.
- name: Vitamin and Cofactor Trials for Treatable Metabolic Causes
  description: >-
    A monitored empiric trial of pyridoxine (for ALDH7A1 pyridoxine-dependent
    epilepsy), pyridoxal 5'-phosphate (PNPO deficiency), folinic acid and biotin
    (biotinidase deficiency) is a priority in any infant presenting with EIDEE,
    because these are the only etiologies with a demonstrably favourable seizure
    outcome. In a prospective EIDEE cohort all metabolic causes were
    vitamin-responsive, and vitamin responsiveness was the only independently
    significant positive predictor of seizure control. Pyridoxine trials require
    cardiorespiratory monitoring because apnoea can occur.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyridoxine
      term:
        id: CHEBI:16709
        label: pyridoxine
    - preferred_term: biotin
      term:
        id: CHEBI:15956
        label: biotin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Etiologic Lesion of the Immature Brain
    treatment_effect: INHIBITS
    description: >-
      Cofactor supplementation corrects the underlying metabolic block in
      vitamin-responsive causes, removing the trigger rather than suppressing
      the downstream discharge.
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with vitamin responsive epilepsies had the best probability of
      seizure control.
    explanation: >-
      The cohort's headline treatment conclusion, directly supporting vitamin
      trials as the highest-yield intervention.
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metabolic testing was diagnostic in three out of 41 patients tested (all
      three had biotinidase deficiency).
    explanation: >-
      Identifies biotinidase deficiency as the specific treatable metabolic
      cause found in this cohort, supporting the biotin arm.
- name: Sodium Channel Blocker Therapy for Gain-of-Function Channelopathies
  description: >-
    Carbamazepine, phenytoin and related sodium-channel blockers are the
    prototype EIDEE precision therapy. In infants with gain-of-function SCN2A,
    SCN3A or SCN8A variants, and in KCNQ2 loss-of-function EIDEE,
    sodium-channel blockade is often markedly more effective than other
    antiseizure medications; the same drugs are contraindicated in SCN1A
    loss-of-function Dravet syndrome, where they aggravate seizures. Because
    EIDEE and Dravet syndrome can both be caused by SCN1A, the functional
    direction of the variant - not the gene name - must drive the prescription.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: carbamazepine
      term:
        id: CHEBI:3387
        label: carbamazepine
    - preferred_term: phenytoin
      term:
        id: CHEBI:8107
        label: phenytoin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Increased Persistent Sodium Current
    treatment_effect: INHIBITS
    description: >-
      Sodium-channel blockade directly counteracts the increased persistent
      inward sodium current produced by gain-of-function variants. The edge
      points at the sodium arm only: the KCNQ2 potassium arm is a
      loss-of-function lesion and its precision target is an M-channel opener,
      not a blocker.
  evidence:
  - reference: PMID:32090326
    reference_title: Biological concepts in human sodium channel epilepsies and their relevance in clinical practice.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      most frequently present with early onset epilepsy (<3 months), and
      demonstrate good response to sodium channel blockers (SCBs)
    explanation: >-
      Directly links the EIDEE onset window to sodium-channel-blocker
      responsiveness in gain-of-function sodium channelopathies.
  - reference: PMID:28379373
    reference_title: Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the use of sodium channel blockers was often associated with clinically
      relevant seizure reduction or seizure freedom in children with early
      infantile epilepsies (<3 months), whereas other antiepileptic drugs were
      less effective
    explanation: >-
      Quantitative clinical support for sodium-channel blockade specifically in
      the under-three-month onset group.
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure freedom is more likely achieved when receiving sodium channel
      blockers.
    explanation: >-
      GeneReviews recommendation for KCNQ2 neonatal-onset DEE.
  notes: >-
    Agents to avoid. The DEE Primer records that sodium-channel blockers may
    exacerbate seizures in SCN1A loss-of-function Dravet syndrome; the same
    caution does not apply to the gain-of-function EIDEE phenotypes described
    here, which is why the functional direction of the variant must be
    established before prescribing.
- name: Conventional Antiseizure Medication
  description: >-
    Phenobarbital, levetiracetam, benzodiazepines, valproate and vigabatrin are
    the conventional first- and second-line antiseizure medications used while
    the etiology is being established and in the majority of infants for whom no
    precision option exists. Phenobarbital, valproic acid and vigabatrin are the
    most commonly used agents in STXBP1 encephalopathy, the commonest
    single-gene EIDEE. Roughly a quarter of STXBP1 patients are refractory to
    antiseizure medication altogether.
  treatment_term:
    preferred_term: Anticonvulsant Therapy
    term:
      id: NCIT:C64172
      label: Anticonvulsant Therapy
    therapeutic_agent:
    - preferred_term: phenobarbital
      term:
        id: CHEBI:8069
        label: phenobarbital
    - preferred_term: levetiracetam
      term:
        id: CHEBI:6437
        label: levetiracetam
    - preferred_term: vigabatrin
      term:
        id: CHEBI:63638
        label: vigabatrin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Burst-Suppression and Hypersynchronous Cortical Discharge
    treatment_effect: INHIBITS
    description: >-
      Conventional antiseizure medications act symptomatically on network
      hypersynchrony rather than on the upstream etiologic lesion.
  evidence:
  - reference: PMID:27905812
    reference_title: STXBP1 Encephalopathy with Epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most commonly used anti-seizure medications (ASMs) are phenobarbital,
      valproic acid, and vigabatrin. About 20% of individuals require more than
      one ASM and approximately 25% are refractory to ASM therapy.
    explanation: >-
      GeneReviews for the commonest EIDEE gene names the conventional ASMs used
      and quantifies refractoriness.
- name: Hormonal Therapy with ACTH or Corticosteroid
  description: >-
    Adrenocorticotropic hormone and high-dose corticosteroid are the standard of
    care once EIDEE evolves into infantile epileptic spasms syndrome (West
    syndrome), the commonest downstream syndrome, typically at 3-6 months as the
    EEG moves from suppression-burst to hypsarrhythmia. Hormonal therapy is far
    less consistently effective for EIDEE in its suppression-burst phase, and
    spasm-phase efficacy should not be read back onto the neonatal phase. No
    `target_mechanisms` edge is declared: the mechanism by which hormonal
    therapy suppresses spasms is not established, and asserting an edge into
    this entry's pathograph would overstate what is known.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticotropin
      term:
        id: CHEBI:3892
        label: corticotropin
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:35765990
    reference_title: "Treatment of children with infantile spasms: A network meta-analysis."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatments including ACTH and high dose prednisolone are more effective in
      achieving electroclinical and clinical remissions for infantile spasms.
    explanation: >-
      Supports hormonal therapy for infantile spasms, the syndrome EIDEE
      characteristically evolves into. Marked PARTIAL because the evidence is
      for the spasms phase, not for EIDEE in its suppression-burst phase.
      Evidence source is HUMAN_CLINICAL: this is a network meta-analysis
      synthesising randomised trials in children, not a narrative review.
  - reference: PMID:11751020
    reference_title: "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Characteristic age-dependent evolution from OS to West syndrome (WS) in
      many cases
    explanation: >-
      Establishes the evolution to West syndrome that makes hormonal therapy
      relevant to the EIDEE care pathway.
- name: Ketogenic Diet
  description: >-
    The ketogenic diet is used for antiseizure-medication-resistant EIDEE and is
    disease-targeted therapy in GLUT1 deficiency. It is feasible in neonates and
    young infants but requires close monitoring: in a neonatal series 40% had a
    good response while the diet had to be suspended in a further 40% because of
    serious adverse effects.
  treatment_term:
    preferred_term: Dietary Intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  therapeutic_modality: BEHAVIORAL
  target_mechanisms:
  - target: Burst-Suppression and Hypersynchronous Cortical Discharge
    treatment_effect: INHIBITS
    description: >-
      Ketosis raises seizure threshold and suppresses network hypersynchrony;
      in GLUT1 deficiency it additionally bypasses the etiologic transport
      defect.
  evidence:
  - reference: PMID:37321250
    reference_title: "Ketogenic Diet in Neonates with Drug-Resistant Epilepsy: Efficacy and Side Effects-A Single Center's Initial Experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diet had a good response in four (40%) patients. In four patients, the
      ketogenic diet was suspended because of the onset of serious side effects.
    explanation: >-
      Gives both the response rate and the tolerability limitation of the
      ketogenic diet in neonates with drug-resistant epilepsy.
  - reference: PMID:37321250
    reference_title: "Ketogenic Diet in Neonates with Drug-Resistant Epilepsy: Efficacy and Side Effects-A Single Center's Initial Experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The ketogenic diet is efficacious and safe in infants, but the early and
      aggressive management of adverse reactions is important to improve the
      safety and effectiveness of the ketogenic treatment.
    explanation: >-
      The authors' overall conclusion on ketogenic diet use in this age group.
- name: Epilepsy Surgery for Resectable Structural Lesions
  description: >-
    Structural etiology accounts for roughly a fifth of EIDEE, and where a
    unifocal resectable lesion such as focal cortical dysplasia is identified,
    surgical resection can be transformative. In a burst-suppression EIDEE
    cohort, surgical resection was effective in patients with cortical dysplasia.
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  therapeutic_modality: SURGERY
  target_mechanisms:
  - target: Etiologic Lesion of the Immature Brain
    treatment_effect: INHIBITS
    description: >-
      Resection removes the structural lesion that is the etiologic trigger,
      rather than modulating the downstream network.
  evidence:
  - reference: PMID:32247221
    reference_title: Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      surgical resection proved to be effective in patients with cortical
      dysplasia
    explanation: >-
      Direct evidence for resective surgery in the structural subgroup of
      early-onset EE with burst suppression.
- name: Multidisciplinary Supportive and Developmental Care
  description: >-
    Because developmental impairment persists even when seizures improve,
    holistic care is essential: feeding and swallowing assessment with
    gastrostomy where needed, respiratory and sleep management, physiotherapy,
    occupational and speech/communication therapy, management of tone and
    movement disorders, vision and hearing services, seizure rescue planning,
    and psychosocial and palliative support.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:27905812
    reference_title: STXBP1 Encephalopathy with Epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment per orthopedics, physical medicine and rehabilitation, physical
      therapy, and occupational therapy to help avoid contractures and falls,
      with positioning and mobility devices as needed.
    explanation: >-
      GeneReviews management recommendations for the commonest EIDEE gene,
      representative of supportive care across the syndrome.
- name: Genetic Counseling
  description: >-
    Most EIDEE-causing dominant variants are de novo, giving a low but non-zero
    recurrence risk; parental mosaicism raises that risk above the conventional
    germline-mosaicism estimate and can be detected with high-depth sequencing.
    Recessive and X-linked diagnoses carry standard recurrence risks and support
    cascade testing, prenatal testing and preimplantation genetic testing.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most individuals diagnosed with KCNQ2-NEO-DEE have a de novo pathogenic
      variant.
    explanation: >-
      GeneReviews establishes the de novo origin that determines counselling for
      the prototypical genetic EIDEE.
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      high-depth sequencing of parental blood or salivary samples found that 8%
      of patients had a parent with low-level mosaicism
    explanation: >-
      Quantifies the parental-mosaicism rate that this counselling
      recommendation depends on, replacing what was previously an unsourced
      claim in the description. Tagged OTHER because this Nat Rev Dis Primers
      narrative review reports the 8% figure secondhand from its own reference
      175 rather than as primary data, consistent with the other twelve items
      citing this review.
definitions:
- name: ILAE 2022 Syndrome Definition of EIDEE
  definition_type: DIAGNOSTIC_CRITERIA
  derivation_basis: ESTABLISHED_CRITERIA
  description: >-
    The ILAE Task Force on Nosology and Definitions defines EIDEE as an epilepsy
    syndrome with seizure onset at or before 3 months of age, frequent
    drug-resistant seizures of multiple types (tonic, clonic, myoclonic, focal,
    epileptic spasms), an abnormal interictal EEG (burst-suppression, multifocal
    epileptiform discharges or hypsarrhythmia), an abnormal neurological
    examination, and developmental impairment. The syndrome subsumes the
    previously separate Ohtahara syndrome and early myoclonic encephalopathy.
    The 2022 position statement publishes per-syndrome tables of mandatory
    features, cautionary alerts and exclusionary features, and provides guidance
    for syndrome diagnosis in resource-limited settings where EEG, MRI and
    genetic testing may be unavailable.
  scope: >-
    Syndrome-level diagnostic criteria applied to neonates and infants with
    seizure onset in the first three months of life.
  inclusion_criteria:
  - preferred_term: Seizure onset at or before 3 months of age
    description: The mandatory age-at-onset criterion that defines the syndrome.
  - preferred_term: Frequent, typically drug-resistant seizures
    description: >-
      Multiple seizure types may occur - tonic, clonic, myoclonic, focal and
      epileptic spasms.
  - preferred_term: Abnormal interictal EEG
    description: >-
      Burst-suppression, multifocal epileptiform discharges, or hypsarrhythmia.
    term:
      id: HP:0002353
      label: EEG abnormality
  - preferred_term: Abnormal neurological examination
    description: >-
      Typically axial hypotonia with or without limb hypertonia or spasticity.
  - preferred_term: Developmental impairment
    description: >-
      Impairment beyond that attributable to the epileptiform activity alone,
      reflecting the developmental as well as the epileptic component.
    term:
      id: HP:0001263
      label: Global developmental delay
  exclusion_criteria:
  - preferred_term: Acute provoked (acute symptomatic) neonatal seizures
    description: >-
      Seizures secondary to an acute reversible insult such as hypoglycaemia,
      hypocalcaemia or acute infection, without an ongoing epilepsy.
  - preferred_term: Self-limited neonatal or infantile epilepsy
    description: >-
      Normal development and normal interictal EEG with spontaneous remission -
      the self-limited arm of the ILAE neonatal/infantile classification.
  - preferred_term: Seizure onset after 3 months of age
    description: >-
      Later onset points to infantile epileptic spasms syndrome, Dravet
      syndrome, or another infantile syndrome.
  evidence:
  - reference: PMID:35503712
    reference_title: "ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The tables summarize mandatory features, cautionary alerts, and
      exclusionary features for the common syndromes.
    explanation: >-
      Establishes that the 2022 position statement is the source of the
      mandatory/cautionary/exclusionary criterion structure used here. Evidence
      source is OTHER because this is a consensus position statement.
  - reference: PMID:35503712
    reference_title: "ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Syndromes are separated into self-limited syndromes, where there is likely
      to be spontaneous remission and developmental and epileptic
      encephalopathies, diseases where there is developmental impairment related
      to both the underlying etiology independent of epileptiform activity and
      the epileptic encephalopathy.
    explanation: >-
      States the self-limited versus DEE dichotomy that underpins the exclusion
      of self-limited neonatal epilepsy from EIDEE. Evidence source is OTHER
      because this is a consensus position statement.
  notes: >-
    The exact mandatory/alert/exclusionary tables are in the full text of the
    position statement; only the abstract is available in the reference cache,
    so the criteria listed here are the syndrome features documented in the
    abstract, the MONDO:0800491 definition, and the primary cohort literature.
differential_diagnoses:
- name: Dravet syndrome
  disease_term:
    preferred_term: Dravet syndrome
    term:
      id: MONDO:0100135
      label: Dravet syndrome
  description: >-
    SCN1A loss-of-function DEE with onset typically at 5-6 months, prolonged
    febrile hemiclonic or generalized seizures, and initially normal development
    and EEG - all outside the EIDEE definition. The distinction is
    treatment-critical: sodium-channel blockers aggravate Dravet syndrome but
    may be the treatment of choice in gain-of-function EIDEE.
  distinguishing_features:
  - Onset at 5-6 months rather than by 3 months
  - Normal development and normal interictal EEG before onset
  - Febrile, often prolonged hemiclonic seizures
  - SCN1A loss-of-function rather than gain-of-function
  evidence:
  - reference: PMID:39237642
    reference_title: Developmental and epileptic encephalopathies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      patients with the non-Dravet, EIDEE phenotype due to GOF variants may
      respond to SCB, such as carbamazepine and phenytoin
    explanation: >-
      Explicitly contrasts the EIDEE phenotype with Dravet syndrome at the level
      of SCN1A variant direction and drug response.
- name: Infantile epileptic spasms syndrome (West syndrome)
  disease_term:
    preferred_term: infantile spasms
    term:
      id: MONDO:0018097
      label: infantile spasms
  description: >-
    Epileptic spasms in clusters with hypsarrhythmia, typically presenting at
    3-12 months. It is both a differential diagnosis and the commonest syndrome
    into which EIDEE evolves; the discriminator is age at onset and the
    interictal EEG pattern at presentation.
  distinguishing_features:
  - Onset typically after 3 months
  - Hypsarrhythmia rather than suppression-burst at presentation
  - Epileptic spasms in clusters as the defining seizure type
  evidence:
  - reference: PMID:33475165
    reference_title: "The severe epilepsy syndromes of infancy: A population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      West syndrome (WS) and "WS-like" epilepsy (infantile spasms without
      hypsarrhythmia or modified hypsarrhythmia) were the most common syndromes
    explanation: >-
      Population-based study distinguishing West syndrome from EIEE as separate
      syndromes with different incidences and outcomes.
- name: Epilepsy of infancy with migrating focal seizures
  disease_term:
    preferred_term: epilepsy of infancy with migrating focal seizures
    term:
      id: MONDO:0017385
      label: malignant migrating partial seizures of infancy
  description: >-
    A distinct neonatal/infantile DEE defined by migrating focal seizures on EEG
    rather than suppression-burst, most often caused by KCNT1 gain-of-function.
    Curated separately in dismech as
    Epilepsy_of_Infancy_with_Migrating_Focal_Seizures; the MONDO term is bound
    here as well so that the differential boundary is machine-queryable. The
    binding uses MONDO:0017385 to match that sibling entry: MONDO:0100025
    carries the obsoletion_candidate subset (the two terms share the
    NANDO:1200595 xref and are duplicate concepts), so MONDO:0017385 is the
    surviving MONDO class for EIMFS. preferred_term keeps the modern ILAE label.
  distinguishing_features:
  - Ictal EEG shows seizures migrating between hemispheres
  - Interictal EEG does not show a persistent suppression-burst pattern
  - Strong association with KCNT1 gain-of-function
  evidence:
  - reference: PMID:33475165
    reference_title: "The severe epilepsy syndromes of infancy: A population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence of epilepsy of infancy with migrating focal seizures (EIMFS)
      was 4.5/100 000 and of early infantile epileptic encephalopathy (EIEE) was
      3.6/100 000.
    explanation: >-
      Treats EIMFS and EIEE as separate, separately enumerated syndromes in a
      population-based cohort.
- name: Self-limited (familial) neonatal epilepsy
  disease_term:
    preferred_term: self-limited familial neonatal epilepsy
    term:
      id: MONDO:0100023
      label: self-limited familial neonatal epilepsy
  description: >-
    Neonatal seizures beginning in otherwise healthy infants in the first days
    of life that remit spontaneously in the first year, with normal development.
    Most commonly caused by inherited KCNQ2 variants - the same gene whose de
    novo loss-of-function variants cause EIDEE - which makes this the single
    most instructive EIDEE differential.
  distinguishing_features:
  - Normal development and normal interictal EEG
  - Spontaneous remission between the first and sixth to twelfth month of life
  - Inherited rather than de novo KCNQ2 variant
  evidence:
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KCNQ2-SLFNE is characterized by seizures that start in otherwise healthy
      infants between two and eight days after term birth and spontaneously
      disappear between the first and the sixth to 12th month of life.
    explanation: >-
      GeneReviews contrasts the self-limited and DEE ends of the KCNQ2
      continuum, which is exactly the differential at issue.
- name: Pyridoxine-dependent and other vitamin-responsive epilepsies
  disease_term:
    preferred_term: pyridoxine-dependent epilepsy
    term:
      id: MONDO:0009945
      label: pyridoxine-dependent epilepsy
  description: >-
    ALDH7A1 pyridoxine-dependent epilepsy, PNPO deficiency, folinic-acid
    responsive seizures and biotinidase deficiency present within the EIDEE
    window and satisfy the EIDEE criteria, but are separable by their dramatic
    response to the relevant vitamin or cofactor and carry a much better seizure
    prognosis. Curated separately as Pyridoxine-Dependent_Epilepsy. Empiric
    monitored vitamin trials should not be delayed pending genetic results. The
    binding deliberately uses the generic parent MONDO:0009945 rather than the
    ALDH7A1-specific MONDO:0020741 bound by that sibling entry, because this
    differential spans PNPO, folinic-acid-responsive and biotinidase deficiency
    as well as ALDH7A1; MONDO:0020741 is a child of MONDO:0009945, so the
    sibling entry still resolves under this term by subsumption.
  distinguishing_features:
  - Dramatic seizure response to pyridoxine, pyridoxal 5'-phosphate, folinic acid or biotin
  - Best probability of seizure control of any EIDEE etiologic group
  evidence:
  - reference: PMID:38074073
    reference_title: "Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      metabolic (14%; all were vitamin responsive)
    explanation: >-
      All metabolic EIDEE causes in this prospective cohort were
      vitamin-responsive, which is what makes this differential actionable.
discussions:
- discussion_id: eidee_ohtahara_eme_merge_residual_structure
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does the ILAE 2022 merge of Ohtahara syndrome and early myoclonic
    encephalopathy into EIDEE discard clinically actionable structure, given
    that the historical split tracked etiology (structural versus metabolic) and
    that the two arms differ in predominant seizure type?
  attaches_to:
  - "pathophysiology#Etiologic Lesion of the Immature Brain"
  rationale: >-
    The 2012 review that argued for unification did so on the basis of
    overlapping clinical presentation, prognosis and EEG signature. But the 2023
    prospective EIDEE cohort found that etiologic group is strongly predictive
    within EIDEE: tonic seizures are enriched in the genetic/unknown group (risk
    ratio 0.66 for the vitamin-responsive/structural group) while clonic
    seizures are enriched in the vitamin-responsive/structural group (risk ratio
    1.36), and severe developmental delay differs by an odds ratio of 57 between
    the groups. That is close to the axis the Ohtahara/EME split was tracking.
    If the seizure-type-plus-etiology structure is reproducible, EIDEE may need
    documented etiologic strata rather than a single undifferentiated syndrome.
  proposed_experiments:
  - experiment_id: exp_eidee_etiology_stratified_seizure_type_cohort
    name: Etiology-stratified prospective EIDEE cohort with seizure-type and EEG phenotyping
    description: >-
      Prospective multi-centre EIDEE cohorts reporting seizure type, interictal
      EEG pattern and outcome stratified by etiologic group, powered to test
      whether the tonic versus myoclonic/clonic distinction is independent of
      etiology.
    decision_criterion: >-
      If seizure type remains associated with the historical Ohtahara/EME split
      after adjustment for etiologic group, the merged syndrome is hiding
      reproducible structure.
  - experiment_id: exp_eidee_historical_series_reclassification
    name: Retrospective reclassification of historical Ohtahara and EME series
    description: >-
      Reclassify published Ohtahara syndrome and early myoclonic encephalopathy
      case series against the ILAE 2022 EIDEE criteria with modern genomic and
      metabolic testing, to determine how cleanly the historical labels map onto
      contemporary etiologic strata.
    decision_criterion: >-
      A clean mapping would indicate the historical labels were etiologic
      proxies; a poor mapping would support the merge.
  evidence:
  - reference: PMID:23044011
    reference_title: "Early-onset epileptic encephalopathies: Ohtahara syndrome and early myoclonic encephalopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Newer understandings of underlying etiologies of these conditions may
      support the previously suggested concept that they represent a single
      spectrum of disease rather than two distinct disorders.
    explanation: >-
      States the unification argument that the ILAE 2022 reclassification
      adopted. Evidence source is OTHER because this is a review article.
- discussion_id: eidee_developmental_vs_epileptic_component
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    In EIDEE specifically, what share of the eventual developmental impairment
    is attributable to the epileptiform activity itself and is therefore
    potentially modifiable by seizure and EEG control, versus fixed by the
    underlying etiology?
  attaches_to:
  - "pathophysiology#Developmental and Epileptic Encephalopathy"
  rationale: >-
    The DEE construct asserts two separable contributors, but at onset before
    three months both act on the same developmental window and the DEE Primer
    states the distinction is often impossible to make. The natural experiment -
    KCNQ2-EIDEE, where seizures remit in over half of patients by age 9 months
    to 4 years yet impairment remains severe to profound - suggests the
    developmental component dominates for at least some genotypes. Resolving
    this determines whether aggressive seizure suppression in the neonatal
    period is developmentally worthwhile or only symptomatically so, and it is
    the central unstated assumption behind every EIDEE precision-therapy trial
    endpoint.
  proposed_experiments:
  - experiment_id: exp_eidee_epileptiform_burden_vs_developmental_quotient
    name: Longitudinal correlation of interictal epileptiform burden with developmental outcome
    description: >-
      Genotype-stratified longitudinal studies correlating quantitative
      interictal epileptiform burden in the first six months with developmental
      quotient at 2 and 5 years, controlling for etiologic group.
    decision_criterion: >-
      An independent association between epileptiform burden and later
      developmental quotient after adjusting for genotype would establish a
      modifiable epileptic component.
  - experiment_id: exp_eidee_eeg_normalization_outcome_comparison
    name: Outcome comparison by early EEG normalization
    description: >-
      Compare developmental outcome between EIDEE infants achieving early
      complete EEG normalization and matched infants with persistent
      epileptiform activity but equivalent clinical seizure control.
    decision_criterion: >-
      Better outcome in the EEG-normalized arm at equivalent seizure control
      would isolate the epileptic contribution to the encephalopathy.
  evidence:
  - reference: PMID:20437616
    reference_title: KCNQ2-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizures generally cease between ages nine months and four years.
    explanation: >-
      Establishes the seizure-remission-without-developmental-recovery pattern
      in KCNQ2-EIDEE that motivates this question; the same GeneReviews entry
      records that moderate-to-profound developmental impairment is present.

📚

References & Deep Research

References

7

PMID:20437616

KCNQ2-Related Disorders.

No top-level findings curated for this source.

PMID:27905812

STXBP1 Encephalopathy with Epilepsy.

No top-level findings curated for this source.

PMID:38603524

CDKL5 Deficiency Disorder.

No top-level findings curated for this source.

PMID:27559564

SCN8A-Related Epilepsy and/or Neurodevelopmental Disorders.

No top-level findings curated for this source.

PMID:35503712

ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions.

No top-level findings curated for this source.

PMID:38074073

Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study.

No top-level findings curated for this source.

PMID:39237642

Developmental and epileptic encephalopathies.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Early-Infantile Developmental and Epileptic Encephalopathy (EIDEE): Research Report

Edison Scientific Literature 21 citations 2026-07-31T23:42:02.309401

Early-Infantile Developmental and Epileptic Encephalopathy (EIDEE): Research Report

Evidence cut-off: emphasis on literature published through 2024. Scope caution: EIDEE is an electroclinical syndrome/class, not one Mendelian disorder. Gene-numbered historical “EIEE” OMIM entries are separate gene-defined diseases and should not be conflated with the umbrella syndrome.

Executive summary

Early-infantile developmental and epileptic encephalopathy is a severe, etiologically heterogeneous epilepsy beginning at or before 3 months of age, accompanied by abnormal EEG activity and impaired development. Contemporary terminology subsumes much of the historical Ohtahara/early-infantile epileptic-encephalopathy spectrum, but not every infant with early seizures has EIDEE: acute provoked neonatal seizures, self-limited genetic neonatal epilepsy, vitamin-responsive epilepsy, structural epilepsy, and infection must be distinguished.

The strongest recent EIDEE-specific dataset is a 2023 prospective cohort of 80 children. Median seizure onset was 28 days; an etiology was established in 83%, comprising genetic 50%, structural 19%, vitamin-responsive metabolic 14%, and unknown 17%. Molecular diagnosis was obtained in 53/77 tested children (69%); 60% remained drug-resistant, 71% had severe developmental delay/intellectual disability, and 14% died during mean 30-month follow-up. These figures are referral-cohort estimates, not population prevalence. (agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 1-3)

A database-ready synopsis is provided below.

domain	key findings/values	suggested ontology identifiers	evidence/source
Disease definition/scope	Early-infantile developmental and epileptic encephalopathy (EIDEE) refers to DEEs with seizure onset by 3 months of age; modern usage encompasses historical early infantile epileptic encephalopathy / Ohtahara-spectrum terminology and emphasizes combined developmental impairment plus epileptic encephalopathy.	MONDO: requires registry verification; MeSH: requires registry verification; ICD-10/11: requires registry verification; HPO candidate terms: Seizure onset in infancy HP:0002373 (verify), Developmental regression/delay terms require verification	(scheffer2024developmentalandepileptic pages 34-39, agarwala2023earlyinfantiledevelopmentaland pages 1-3)
Cohort demographics	Prospective EIDEE cohort: 80 children, male:female 1.5:1, median seizure onset 28 days (range 1–90), mean follow-up 30 months.	NCIT/phenotype ontology not essential; Age of onset ontology terms require verification	(agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 1-3)
Etiologic distribution	Confirmed etiology in 66/80 (83%): genetic 50%, structural 19%, metabolic 14% (all vitamin-responsive), unknown 17%.	MONDO disease grouping requires verification; HPO: Abnormality of metabolism / structural brain abnormality terms require verification	(agarwala2023earlyinfantiledevelopmentaland pages 1-3)
Seizure/EEG phenotype	Common seizure types included clonic, tonic, myoclonic; EEG: burst-suppression 42%, multifocal discharges 30%, hypsarrhythmia 13%.	HPO candidates: Burst suppression on EEG HP:0010849 (verify); Hypsarrhythmia HP:0002521 (verify); Myoclonic seizure HP:0002123 (verify); Tonic seizure HP:0002069 (verify); Clonic seizure HP:0002266 (verify)	(agarwala2023earlyinfantiledevelopmentaland pages 4-6)
Neurodevelopmental/behavioral phenotype	Genetic/unknown etiologies showed more severe neurodevelopmental burden than vitamin-responsive/structural groups: severe DD/ID OR 57, autistic behaviors OR 37, tone abnormalities OR 9, movement disorder OR 19.	HPO candidates: Global developmental delay HP:0001263 (verify); Intellectual disability HP:0001249 (verify); Autism HP:0000717 (verify); Abnormality of muscle tone HP:0003808 (verify); Movement disorder HP:0100022 (verify)	(agarwala2023earlyinfantiledevelopmentaland pages 1-3, agarwala2023earlyinfantiledevelopmentaland pages 8-10)
MRI/metabolic findings	MRI abnormal in 35/80 (44%); among abnormal MRIs, 16/35 had malformations and 19/35 nonspecific changes. Metabolic testing diagnostic in 3/41, all biotinidase deficiency in the prospective cohort summary.	UBERON brain UBERON:0000955; HPO candidate: Abnormal brain MRI HP:0012443 (verify); Biotinidase deficiency disease ontology requires verification	(agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 1-3)
Outcomes/prognosis	At follow-up: 71% had severe developmental delay/intellectual disability, 60% remained drug-resistant, 14% died. Vitamin-responsive etiologies had the best probability of seizure control; only vitamin-responsive etiology had significant positive effect on seizure control (P=0.02).	HPO candidates: Drug resistant epilepsy requires verification; Severe global developmental delay requires verification; Mortality not typically HPO-coded	(agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 1-3)
Genetic architecture	DEEs are highly heterogeneous; 2024 review notes ~50% of DEE patients overall receive a molecular diagnosis, and by 2023 825 DEE-associated genes were cataloged among 925 monogenic epilepsy genes.	HGNC gene symbols as listed; MONDO/GENO mappings require verification	(scheffer2024developmentalandepileptic pages 9-11, scheffer2024developmentalandepileptic pages 19-21)
Major mechanism class: ion channelopathies	Representative early-infantile DEE genes include SCN1A, SCN2A, SCN3A, SCN8A, KCNQ2, KCNT1, SCN1B, nicotinic receptor genes. Functional direction matters: GOF variants may benefit from inhibitory/channel-blocking strategies; LOF variants may require augmentation approaches.	GO: ion transmembrane transport GO:0034220; GO: regulation of membrane potential GO:0042391; CL terms for excitatory/inhibitory neurons require verification	(specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 6-8)
Representative gene-mechanism examples	SCN2A GOF → neonatal-onset epilepsy, often responsive to sodium-channel blockers; SCN2A LOF → later-onset generalized seizures/poorer response. SCN8A GOF can cause infantile epilepsies/DEE. KCNT1 GOF increases current; quinidine has variable benefit. KCNQ2 is a key early-infantile potassium-channel DEE gene.	HGNC: SCN2A, SCN8A, KCNT1, KCNQ2; GO annotations above; variant mechanism ontology requires verification	(specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 19-21)
Synaptic/synaptopathy mechanisms	Synaptopathies are a major DEE class; STXBP1 was the most common single-gene diagnosis in the prospective EIDEE cohort (5 patients). DEE mechanisms include disrupted SNARE machinery, synaptic scaffolds, and post-synaptic receptor dysfunction.	HGNC: STXBP1; GO: synaptic vesicle exocytosis GO:0016079; GO: chemical synaptic transmission GO:0007268	(agarwala2023earlyinfantiledevelopmentaland pages 1-3, scheffer2024developmentalandepileptic pages 34-39)
Other mechanism classes	Additional DEE mechanisms include mTOR-pathway dysregulation (e.g., DEPDC5 negative regulator; second-hit/somatic LOH in focal cortical dysplasia), ubiquitination/post-translational pathways (e.g., UBA5, KLHL20, WWOX), transporter dysfunction, and transcriptional/epigenetic regulation abnormalities.	GO: TOR signaling GO:0031929; GO: protein ubiquitination GO:0016567; GO: regulation of transcription GO:0006355; CL/UBERON terms require verification	(specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 9-11, scheffer2024developmentalandepileptic pages 34-39)
Cell/tissue emphasis	Reviews highlight dysfunction in cortical/telencephalic parvalbumin-positive inhibitory interneurons in some sodium-channel DEEs, alongside roles for excitatory neurons and glia.	CL: parvalbumin-positive interneuron requires verification; UBERON: cerebral cortex UBERON:0000956 (verify); GO CC plasma membrane GO:0005886	(scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 6-8)
Diagnostic workflow	Recommended workup: video-EEG, 3T epilepsy-protocol brain MRI, early blood/urine metabolic testing, CSF studies when indicated, and rapid genomic testing. Genetic strategy commonly starts with CMA for CNVs then NGS/exome; genome sequencing is entering practice. High-depth methods may be needed for mosaicism.	LOINC/NCIT assay codes require verification; HPO/UBERON as above	(scheffer2024developmentalandepileptic pages 11-13, scheffer2024developmentalandepileptic pages 13-15, nguyen2024genotypedriventherapeuticsin pages 9-10, agarwala2023earlyinfantiledevelopmentaland pages 1-3)
Diagnostic yield data	In the EIDEE cohort, molecular diagnosis in 53/77 (69%) tested; NGS yield 51%, microarray yield 14%. A 2024 review cites pathogenic variants identified in ~50% of DEE patients overall. Rapid genome sequencing in infants <1 year with seizures found genetic etiology in 46% with median 37 days to diagnosis.	CMA/exome/genome ontology identifiers require verification	(agarwala2023earlyinfantiledevelopmentaland pages 1-3, scheffer2024developmentalandepileptic pages 11-13, scheffer2024developmentalandepileptic pages 9-11)
Treatable mimics / metabolic-vitamins	Early evaluation should prioritize treatable and vitamin-responsive epilepsies. Reported empiric trials include pyridoxine, pyridoxal 5'-phosphate, folinic acid, biotin; vitamin-responsive etiologies had the most favorable seizure-control outcomes in the prospective cohort.	CHEBI/DrugBank IDs require verification; NCIT intervention terms for pyridoxine/biotin/folinic acid require verification	(scheffer2024developmentalandepileptic pages 13-15, agarwala2023earlyinfantiledevelopmentaland pages 1-3)
Genotype-guided pharmacotherapy	Sodium-channel blockers may be effective in selected GOF channelopathies; cohort examples with benefit included SCN1A, KCNQ2, FGF12, SCN8A, SCN2A (6 patients total). Quinidine benefited one KCNT1 patient in the cohort.	NCIT: Carbamazepine/Phenytoin/Lacosamide/Quinidine require verification; CHEBI drug IDs require verification	(agarwala2023earlyinfantiledevelopmentaland pages 8-10, specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 13-15)
Important cautions	Precision treatment must consider direction of effect. In Dravet syndrome / SCN1A LOF, carbamazepine/oxcarbazepine can worsen seizures and should be avoided, whereas sodium-channel blockers may help some SCN2A/SCN8A/KCNQ2 GOF cases.	NCIT drug terms require verification; disease-specific MONDO IDs require verification	(scheffer2024developmentalandepileptic pages 9-11, specchio2024theexpandingfield pages 8-11)
Diet therapy	Ketogenic diet is used for ASM-resistant DEE and was described as an early treatment option in genotype-driven DEE management; one 2024 cohort/review context reported approximately 30% seizure freedom and 60% >50% seizure reduction in young patients with EIDEE/related DEEs.	NCIT: Ketogenic Diet requires verification	(nguyen2024genotypedriventherapeuticsin pages 9-10)
Surgery/interventional care	For unifocal resectable structural lesions (e.g., focal cortical dysplasia), epilepsy surgery evaluation is recommended and can be transformational.	NCIT: Epilepsy surgery requires verification; UBERON lesion-specific anatomy requires verification	(scheffer2024developmentalandepileptic pages 11-13)
Supportive/holistic care	Holistic care is necessary because long-term developmental outcomes are often abnormal despite seizure treatment; common needs include management of motor dysfunction, psychiatric features, speech and sleep problems, developmental therapies, and family support.	HPO candidates: Sleep disturbance / speech delay / motor delay require verification; NCIT rehab/supportive care terms require verification	(scheffer2024developmentalandepileptic pages 9-11)
Inheritance/counseling	In the EIDEE cohort’s pathogenic variants, 67% autosomal dominant and 33% autosomal recessive inheritance were reported. High-depth sequencing detects parental mosaicism; one review reported mosaicism in 8% of apparently de novo cases, relevant to recurrence-risk counseling and prenatal/IVF options.	GENO inheritance terms require verification	(agarwala2023earlyinfantiledevelopmentaland pages 4-6, scheffer2024developmentalandepileptic pages 13-15)
Experimental therapies	Emerging precision therapies include antisense oligonucleotides (ASOs) and gene-augmentation/activation strategies. Examples from DEE reviews: STK-001 for SCN1A/Dravet (TANGO strategy), exploratory SCN2A ASO approaches, and AAV-mediated gene therapy concepts.	NCIT: Antisense oligonucleotide therapy / Gene therapy require verification	(specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 17-19, specchio2024theexpandingfield pages 27-29)
Experimental models	Model systems cited across DEE reviews include mouse, iPSC-derived neurons, and other preclinical platforms. Dravet/iPSC data show selective impairment of inhibitory neurons; mouse models demonstrated rescue with AAV-SCN1A, CRISPRa/dCas9 activation, and cell-selective GABAergic targeting.	CL: induced pluripotent stem cell-derived neuron requires verification; NCBITaxon mouse NCBITaxon:10090; GO/CL interneuron terms require verification	(specchio2024theexpandingfield pages 27-29, scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 14-17)
Real-world implementation / trial landscape	Active interventional DEE trials retrieved included NCT07019922 (elsunersen in pediatric SCN2A-DEE, recruiting), NCT05737784 (PRAX-222 in early-onset SCN2A-DEE, recruiting), NCT04639310 / NCT04912856 (XEN496/ezogabine in KCNQ2-DEE, terminated), NCT06983158 (CAP-002 gene therapy for STXBP1 encephalopathy, terminated), and broad DEE programs such as relutrigine NCT07010471 and LP352 NCT06719141/NCT06908226.	ClinicalTrials.gov NCT identifiers as listed; NCIT interventions require verification	Retrieved clinical trial records in prior tool output; narrative support from (specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 17-19)

Table: This table summarizes core disease-definition, cohort, mechanistic, diagnostic, therapeutic, and translational findings for Early-Infantile Developmental and Epileptic Encephalopathy. It is formatted for direct knowledge-base curation and flags ontology identifiers that require external registry verification.

1. Disease information

Definition and nomenclature

EIDEE denotes a developmental and epileptic encephalopathy with seizure onset by 3 months, developmental impairment attributable both to the underlying cause and potentially to epileptic activity, and a markedly abnormal EEG. Frequent seizures, including tonic, clonic, myoclonic, focal, and epileptic spasms, are typical. Burst suppression is characteristic but not obligatory; multifocal discharges or hypsarrhythmia may occur. (agarwala2023earlyinfantiledevelopmentaland pages 4-6, scheffer2024developmentalandepileptic pages 34-39)

Synonyms/related terms: early-infantile DEE; early infantile developmental and epileptic encephalopathy; neonatal-onset DEE; historical early infantile epileptic encephalopathy; Ohtahara syndrome; early myoclonic encephalopathy. The latter historical syndromes overlap the modern category but should remain searchable synonyms rather than exact equivalents in every record.

Identifiers: a single stable umbrella MONDO/OMIM/Orphanet identifier could not be verified from the retrieved primary literature. OMIM mainly represents gene-specific EIEE-numbered entities. ICD-10-CM generally codes the manifestations under epilepsy/epileptic encephalopathy rather than providing a sufficiently specific EIDEE code. ICD-11 and current MONDO entries should therefore be validated directly against the release used by the target knowledge base. MeSH indexing generally falls under Epileptic Encephalopathies.

The evidence summarized here is aggregated disease-level evidence from cohorts and reviews, not individual EHR data. Individual case/trial observations are identified as such.

2. Etiology, risk, and protective factors

EIDEE is a final common phenotype rather than a single genetic disease. In the 2023 cohort, causes were genetic in 50%, structural in 19%, vitamin-responsive metabolic in 14%, and unresolved in 17%. Relevant structural causes include malformations of cortical development and acquired neonatal injuries such as hypoxic–ischemic injury, stroke, infection, hypoglycemia, or trauma. (agarwala2023earlyinfantiledevelopmentaland pages 1-3, scheffer2024developmentalandepileptic pages 34-39)

Genetic risk

Major mechanistic groups include:

Ion-channel disorders: SCN1A, SCN2A, SCN3A, SCN8A, SCN1B, KCNQ2, KCNB1, KCNT1, KCNA2, and calcium/receptor-channel genes.
Synaptic-vesicle and synaptic-signaling disorders: STXBP1, DNM1, SNAP25, NECAP1, NBEA, and glutamate/GABA-receptor genes.
Kinase/transcription/chromatin disorders: CDKL5, CSNK2B, ARX, FOXG1, CHD2 and related regulators.
mTOR/cortical-malformation disorders: TSC1, TSC2, DEPDC5, NPRL2, NPRL3, MTOR and mosaic PI3K–AKT–mTOR-pathway variants.
Transport/metabolic/mitochondrial disorders: SLC2A1, SLC6A1, ATP1A3, ALDH7A1, PNPO, BTD, POLG and mitochondrial genes.
Ubiquitination/cellular-homeostasis disorders: biallelic UBA5 and WWOX, and dominant KLHL20. (specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 9-11, scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 1-6)

Variants may be missense, nonsense, frameshift, splice-altering, copy-number, structural, or mosaic. Most severe dominant channel/synaptic DEEs arise through germline de novo variants, whereas metabolic and several cellular-homeostasis disorders are autosomal recessive. X-linked disorders include CDKL5 and ARX. In the 2023 cohort, 67% of pathogenic findings followed dominant and 33% recessive inheritance. (agarwala2023earlyinfantiledevelopmentaland pages 4-6)

Allele frequency must be assessed per variant in gnomAD and ClinVar; pathogenic dominant EIDEE variants are ordinarily absent or exceptionally rare in population databases. ACMG classification and functional direction must be recorded separately. A VUS is not diagnostic without segregation, phenotype, and/or functional evidence.

Environmental, lifestyle, infectious, and protective factors

There is no established lifestyle exposure that causes the primary genetic syndrome, and no validated protective allele or diet that prevents it. Fever, infection, sleep deprivation, and metabolic stress can precipitate seizures in an affected child but are generally triggers, not causes. Prenatal/perinatal infection and hypoxic–ischemic injury are etiologic alternatives or structural causes. Inflammation may amplify channelopathy phenotypes in experimental systems, but a general human gene–environment model is not established. (specchio2024theexpandingfield pages 14-17)

3. Phenotypes and quality-of-life impact

The 80-child prospective cohort reported burst suppression in 42%, multifocal discharges in 30%, and hypsarrhythmia in 13%. Severe DD/ID affected 71% at follow-up. Relative to structural/vitamin-responsive cases, genetic/unknown cases had much higher odds of severe DD/ID (OR 57), autistic behavior (OR 37), tone abnormalities (OR 9), and movement disorder (OR 19). (agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 1-3, agarwala2023earlyinfantiledevelopmentaland pages 8-10)

Suggested phenotype annotations include:

early-infantile seizure onset; neonatal seizure; focal, tonic, clonic, myoclonic seizures; epileptic spasms;
burst-suppression EEG, multifocal epileptiform discharges, hypsarrhythmia;
global developmental delay (HP:0001263), intellectual disability (HP:0001249), developmental stagnation/regression;
hypotonia, hypertonia/spasticity, dystonia, chorea, tremor, or other movement disorder;
microcephaly, feeding/swallowing dysfunction, growth failure, cortical visual impairment;
autistic behavior (HP:0000729 should be registry-checked), sleep disturbance, absent or limited speech.

The burden is typically profound: frequent seizures and rescue-medication use, impaired mobility and communication, feeding/respiratory complications, disrupted sleep, repeated hospitalizations, and lifelong caregiver dependence. Formal EIDEE-specific EQ-5D/SF-36 norms were not found; generic pediatric quality-of-life instruments may underrepresent profound neurodisability.

4. Genetic and molecular information

Functional interpretation is essential because the same gene can require opposite treatment depending on variant effect:

SCN2A gain-of-function (GOF) variants typically produce neonatal/early-infantile focal epilepsy and may respond to phenytoin, carbamazepine, or lacosamide; loss-of-function (LOF) more often causes later developmental phenotypes and should not automatically be treated the same way.
SCN8A GOF increases Nav1.6-mediated excitability and can cause infantile DEE; LOF is associated with different, often later phenotypes.
SCN1A haploinsufficiency impairs firing of GABAergic inhibitory interneurons in Dravet syndrome; sodium-channel blockers may worsen this LOF disorder. Rare SCN1A GOF phenotypes require separate interpretation.
KCNQ2 LOF reduces M-current, weakening neuronal repolarization and increasing excitability.
KCNT1 GOF increases sodium-activated potassium-channel current and causes severe early epilepsy; quinidine is mechanistically plausible but clinical efficacy and tolerability are inconsistent.
STXBP1 haploinsufficiency disrupts SNARE-mediated synaptic-vesicle release; it was the most frequent single-gene finding in the 2023 cohort (5 children).
DEPDC5 loss disinhibits mTORC1; a somatic second hit can generate focal cortical dysplasia. (agarwala2023earlyinfantiledevelopmentaland pages 1-3, specchio2024theexpandingfield pages 27-29, specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 19-21)

No syndrome-wide epigenetic signature is established. Chromatin-regulator genes can cause DEE, and somatic mosaicism is important in cortical malformations. CNVs are clinically relevant: microarray detected diagnoses in 14% of the EIDEE cohort, although broader DEE reviews estimate approximately 4% in less selected populations. (agarwala2023earlyinfantiledevelopmentaland pages 1-3, scheffer2024developmentalandepileptic pages 11-13)

5. Mechanism and pathophysiology

A generalized causal chain is:

pathogenic variant/brain lesion/metabolic deficiency → altered neurodevelopment, synaptic release, receptor signaling, ion conductance, or energy metabolism → excitation–inhibition imbalance in immature cortical networks → recurrent seizures and epileptiform EEG activity → activity-dependent network injury layered upon the primary developmental defect → developmental stagnation/regression and neurological comorbidity.

Upstream mechanisms include altered cortical progenitor development, neuronal migration, channel biophysics, SNARE release, transcription/chromatin regulation, and mTOR signaling. Downstream mechanisms include network hypersynchrony, excitotoxic/oxidative stress, sleep disruption, neuroinflammation, and impaired activity-dependent circuit maturation. The relative contribution of the primary developmental defect versus seizures differs by genotype. (scheffer2024developmentalandepileptic pages 34-39, specchio2024theexpandingfield pages 6-8, specchio2024theexpandingfield pages 1-6)

Suggested annotations include GO:0042391 regulation of membrane potential, GO:0034220 ion transmembrane transport, GO:0007268 chemical synaptic transmission, GO:0016079 synaptic-vesicle exocytosis, GO:0031929 TOR signaling, and GO:0016567 protein ubiquitination. Relevant cells include glutamatergic neurons, GABAergic interneurons—especially parvalbumin-positive interneurons in selected sodium channelopathies—radial/apical neural progenitors, and glia. Relevant compartments include plasma membrane/axon initial segment, presynaptic active zone and synaptic vesicle, postsynaptic membrane, nucleus/chromatin, mitochondrion, and lysosome. (scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 6-8)

Disease-wide transcriptomic, proteomic, metabolomic, lipidomic, single-cell, and spatial signatures are not sufficiently replicated for clinical annotation. Such findings are mainly gene-specific and preclinical.

6. Anatomy

The primary organ is the central nervous system, especially bilateral cerebral cortex and distributed thalamocortical networks. Structural subgroups may involve focal cortex, hippocampus, basal ganglia, cerebellum, or diffuse malformations. Suggested terms include UBERON:0000955 brain and UBERON:0000956 cerebral cortex. There is generally no fixed lateralization unless a focal malformation or stroke is causal. Secondary involvement includes musculoskeletal contractures from immobility/spasticity, aspiration-related respiratory disease, gastrointestinal feeding problems, impaired growth, and sleep/autonomic dysfunction.

7. Temporal development and natural history

Onset is neonatal or within the first three postnatal months and may be abrupt, with clusters, status epilepticus, or rapidly increasing seizure burden. In the 2023 cohort, 32.5% began within 7 days and median onset was 28 days. Evolution to infantile epileptic spasms syndrome or later multifocal/Lennox–Gastaut-like epilepsy may occur. The course is chronic and often drug-resistant rather than classically relapsing–remitting. Seizure remission does not guarantee developmental recovery because the genetic/structural disorder has independent developmental effects. (agarwala2023earlyinfantiledevelopmentaland pages 4-6)

Early infancy is the critical diagnostic and therapeutic period: treatable metabolic disease, resectable structural lesions, and mechanism-specific channel therapy should be identified before prolonged status epilepticus and disrupted circuit maturation.

8. Epidemiology, inheritance, and population

Robust population incidence or prevalence for the umbrella EIDEE syndrome is unavailable. A tertiary-center cohort cannot supply population prevalence. Syndrome-specific Scottish estimates cited in a 2024 review include CDKL5-DEE incidence of 2.36 per 100,000 live births and PCDH19 clustering epilepsy of 4.85 per 100,000, but these are not EIDEE-wide estimates. (scheffer2024developmentalandepileptic pages 34-39)

Both sexes are affected; sex ratios vary by gene. The 2023 cohort had a male:female ratio of 1.5:1, but this should not be generalized globally. X-linked disorders create gene-specific sex effects. No consistent ethnic/geographic predisposition is established; ascertainment and access to sequencing strongly affect reported distributions. (agarwala2023earlyinfantiledevelopmentaland pages 4-6)

Penetrance is often high for severe de novo variants but is gene/variant-specific. Expressivity is variable. Anticipation is not a general feature. Parental mosaicism was reported in approximately 8% of apparently de novo DEE cases when sensitive methods were used; recurrence risk can therefore exceed the conventional ~1% germline-mosaicism estimate. Recessive disease risk rises with consanguinity, and founder variants may be population-specific. (scheffer2024developmentalandepileptic pages 13-15)

9. Diagnosis

Recommended workflow

Stabilize and document seizures: continuous or prolonged video-EEG is essential because neonatal seizures may be electrographic-only. Characterize background, burst suppression, multifocal activity, and spasms.
Identify acquired causes urgently: glucose, electrolytes, calcium/magnesium, blood gas, CBC/cultures, infection testing, and assessment for hypoxic–ischemic injury, hemorrhage, stroke, or trauma.
MRI: 3-T epilepsy-protocol MRI, including diffusion and susceptibility sequences, to identify malformation, ischemia, hemorrhage, or focal cortical dysplasia. (scheffer2024developmentalandepileptic pages 11-13)
Treatable metabolic testing: ammonia, lactate/pyruvate, plasma amino acids, acylcarnitines, urine organic acids, biotinidase, and targeted CSF glucose, lactate, amino acids, and neurotransmitters when indicated. Prioritize ALDH7A1, PNPO, BTD, SLC2A1, mitochondrial and POLG-related disease. (scheffer2024developmentalandepileptic pages 13-15)
Do not delay monitored vitamin trials when appropriate: pyridoxine, pyridoxal-5′-phosphate, folinic acid, and biotin, with cardiorespiratory/EEG monitoring because pyridoxine can cause apnea. In the cohort, metabolic testing diagnosed biotinidase deficiency in 3/41 tested children, and all metabolic etiologies were vitamin-responsive. (agarwala2023earlyinfantiledevelopmentaland pages 1-3)
Rapid trio exome or genome sequencing: increasingly favored early because of high heterogeneity and time-sensitive treatment. Rapid genome sequencing in infants under one year with seizures found an etiology in 46% at median 37 days; overall NGS identifies about half of DEE. (scheffer2024developmentalandepileptic pages 9-11)
CNV and mosaic analysis: ensure exon-level CNV calling; use CMA if not captured or when dysmorphism/malformation suggests CNV. Consider deep sequencing, affected-tissue sequencing, or droplet-digital PCR for low-level mosaicism. (scheffer2024developmentalandepileptic pages 11-13)
Reanalysis: periodically reanalyze negative exome/genome data; consider mtDNA, repeat expansion, RNA sequencing, methylation signatures, or functional assays when phenotype directs. Karyotype/FISH is not first-line unless a cytogenetic rearrangement is suspected.

The prospective study’s exact abstract statement was: “A molecular diagnosis was achieved in 53 out of 77 patients tested (69%). Next-generation sequencing had a yield of 51%, while microarray had a yield of 14%.” (Publication: 14 September 2023; DOI URL: https://doi.org/10.1093/braincomms/fcad243.) (agarwala2023earlyinfantiledevelopmentaland pages 1-3)

Differential diagnosis

Exclude acute symptomatic neonatal seizures, self-limited familial neonatal/infantile epilepsy, infantile epileptic spasms syndrome, epilepsy of infancy with migrating focal seizures, Dravet syndrome, glycine encephalopathy, pyridoxine/PNPO/folinic-acid-responsive epilepsy, biotinidase deficiency, GLUT1 deficiency, mitochondrial disease, congenital infection, autoimmune encephalitis, hypoxic–ischemic injury, stroke, and structural malformation. EEG pattern alone is not etiologic.

10. Outcomes and prognosis

In the 2023 prospective cohort, 60% remained drug-resistant, 71% had severe DD/ID, and 14% died over mean 30 months. Median time to seizure control was 3 days for vitamin-responsive disease versus 75 days structural, 80 days unknown, and 90 days genetic. Vitamin responsiveness was the only independently significant favorable seizure-control factor (P=0.02). (agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 8-10)

Mortality mechanisms include status epilepticus, respiratory/aspiration complications, infection, underlying metabolic disease, and sudden unexpected death in epilepsy. There are no reliable syndrome-wide 5- or 10-year survival estimates. Favorable prognostic factors include an immediately treatable metabolic deficiency, a completely resectable lesion, and early mechanism-matched treatment. Severe neonatal EEG background abnormality, persistent status, profound early developmental impairment, and drug resistance generally indicate poorer outcomes.

11. Treatment and real-world implementation

Acute and conventional treatment

Treat status epilepticus according to neonatal/pediatric protocols while pursuing etiology. Phenobarbital, levetiracetam, benzodiazepines, phenytoin/fosphenytoin, and other ASMs are selected according to seizure type, age, organ function, and suspected mechanism. No single ASM treats all EIDEE.

Genotype/etiology-guided treatment

Vitamin-dependent epilepsy: pyridoxine for ALDH7A1; pyridoxal-5′-phosphate for PNPO; folinic acid in selected responsive disorders; biotin for biotinidase deficiency.
SCN2A/SCN8A GOF and some KCNQ2 early-onset disease: sodium-channel blockers may be unusually effective. Six genotype-guided responders in the 2023 cohort carried SCN1A, KCNQ2, FGF12, SCN8A, or SCN2A findings. (agarwala2023earlyinfantiledevelopmentaland pages 8-10, specchio2024theexpandingfield pages 8-11)
SCN1A-LOF/Dravet: avoid maintenance carbamazepine and oxcarbazepine because seizure aggravation can occur; use syndrome-supported regimens such as valproate, clobazam, stiripentol, cannabidiol, and fenfluramine as clinically appropriate. (scheffer2024developmentalandepileptic pages 9-11)
KCNT1 GOF: quinidine is experimental/off-label; one cohort child benefited, but ECG/QT and drug-interaction monitoring is mandatory and responses are variable. (agarwala2023earlyinfantiledevelopmentaland pages 8-10, specchio2024theexpandingfield pages 8-11)
mTORopathy: everolimus has established evidence for tuberous-sclerosis-complex-associated seizures, not for EIDEE indiscriminately.
GLUT1 deficiency: ketogenic diet is disease-targeted therapy.

The ketogenic diet is also used for drug-resistant EIDEE. A 2024 study reported approximately 30% seizure freedom and 60% achieving >50% seizure reduction in the relevant young-patient context, but these uncontrolled results should not be interpreted as a universal EIDEE response rate. (nguyen2024genotypedriventherapeuticsin pages 9-10)

For a unifocal, resectable lesion, early epilepsy-surgery assessment can be transformative. Palliative options for persistent generalized/multifocal disease include vagus-nerve stimulation, corpus callosotomy, and other neuromodulation, although EIDEE-specific comparative evidence is limited. (scheffer2024developmentalandepileptic pages 11-13)

Supportive care requires feeding/swallow assessment, nutrition and gastrostomy when needed, respiratory and sleep management, physiotherapy, occupational/speech/communication therapy, management of tone and movement disorders, vision/hearing services, rescue plans, SUDEP counseling, psychosocial support, and palliative-care involvement where appropriate. Suggested NCIT mappings include Anticonvulsant Therapy, Ketogenic Diet Therapy, Epilepsy Surgery, Vagus Nerve Stimulation, Physical Therapy, Occupational Therapy, Speech Therapy, Genetic Counseling, Antisense Oligonucleotide Therapy, and Gene Therapy; local NCIT concept codes should be release-verified.

12. 2023–2024 research developments and trials

The major conceptual advance is movement from gene-name prescribing toward variant-mechanism prescribing. The 2024 Lancet review emphasizes that GOF should generally be reduced, whereas LOF/haploinsufficiency may require transcript or gene augmentation. (specchio2024theexpandingfield pages 8-11, specchio2024theexpandingfield pages 6-8)

Emerging approaches include ASOs, AAV gene replacement, CRISPR activation, and stop-codon read-through. In mouse Dravet models, AAV-mediated SCN1A augmentation and dCas9/CRISPRa activation improved seizures and survival; cell-selective targeting of inhibitory neurons is particularly relevant. Patient-derived iPSC neurons demonstrate impaired inhibitory-neuron excitability in SCN1A disease. These are preclinical findings and do not establish routine efficacy. (specchio2024theexpandingfield pages 27-29, scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 14-17, scheffer2024developmentalandepileptic pages 17-19)

Retrieved ClinicalTrials.gov records included:

NCT05737784: PRAX-222/elsunersen-like SCN2A-lowering ASO program for early-onset SCN2A-DEE; phase 1/2, 60 planned, recruiting in the retrieved record.
NCT07019922: elsunersen in pediatric SCN2A-DEE; phase 3, 40 planned, recruiting.
NCT04639310/NCT04912856: XEN496 (ezogabine) and extension in KCNQ2-DEE; both terminated, enrollment 8.
NCT04937062: phenylbutyrate for monogenic DEE; early phase 1, 50 planned, active-not-recruiting.
NCT04873869/NCT05226780: NBI-921352 for SCN8A-DEE and extension; terminated, enrollment 8.
NCT06983158: CAP-002 gene therapy for STXBP1 encephalopathy; phase 1/2, terminated after enrollment of 1 in the retrieved record.

Trial statuses are dynamic and must be rechecked at https://clinicaltrials.gov before curation or clinical use.

13. Prevention

There is no vaccine, lifestyle modification, or population-screening program that prevents sporadic de novo EIDEE. Primary prevention is therefore reproductive rather than behavioral: molecular diagnosis, parental high-depth testing, counseling about gonadal/somatic mosaicism, preimplantation genetic testing, chorionic-villus sampling, or amniocentesis. (scheffer2024developmentalandepileptic pages 13-15)

Secondary prevention consists of rapid recognition, EEG confirmation, early genomic diagnosis, and immediate treatment of vitamin-responsive/metabolic disease or a resectable lesion. Tertiary prevention includes seizure-rescue plans, aspiration and infection prevention, nutrition, contracture prevention, bone health, SUDEP counseling, and rehabilitation. Cascade/carrier testing applies to inherited dominant, recessive, X-linked, or mitochondrial diagnoses; universal newborn screening for EIDEE is not currently established.

14. Other species and natural disease

No unitary, naturally occurring veterinary syndrome equivalent to human EIDEE was established in the retrieved evidence. Orthologous channel, synaptic, and metabolic diseases occur in animals, but annotation should be made at the gene-specific level through OMIA rather than assigning the entire human umbrella syndrome. The condition is not infectious or zoonotic and has no cross-species transmission.

15. Model organisms

Mouse (NCBITaxon:10090): heterozygous/conditional Scn1a models reproduce spontaneous seizures, temperature sensitivity, premature death, and inhibitory-interneuron dysfunction; Scn2a, Scn8a, Kcnq2, Stxbp1, and Cdkl5 models capture selected seizure/developmental phenotypes. Genetic background strongly changes severity.
Zebrafish (NCBITaxon:7955): scalable seizure and drug-screening models exist for several channel/synaptic genes, but brain development and pharmacokinetics limit direct translation.
Drosophila/C. elegans: useful for conserved ion-channel and synaptic pathways, with limited representation of mammalian cortical circuitry.
Patient iPSC-derived neurons and cerebral organoids: enable variant-specific electrophysiology, GOF/LOF assignment, rescue experiments, and study of human progenitor/circuit phenotypes. Limitations include cellular immaturity, line-to-line variation, and absence of whole-organism pharmacology. In SCN1A iPSC systems, inhibitory neurons show selective functional impairment. (scheffer2024developmentalandepileptic pages 19-21)

The best-supported applications are mechanism validation, functional classification of VUS, drug screening, therapeutic-window studies, and testing ASO/AAV/CRISPR strategies. Experimental rescue in a model does not itself prove clinical efficacy.

Evidence limitations and authoritative interpretation

The 2024 Nature Reviews Disease Primers and Lancet Child & Adolescent Health reviews support rapid molecular diagnosis and mechanism-stratified therapy, while emphasizing that DEEs encompass hundreds of genes and that developmental morbidity often persists despite seizure improvement. (scheffer2024developmentalandepileptic pages 34-39, specchio2024theexpandingfield pages 8-11, specchio2024theexpandingfield pages 1-6, scheffer2024developmentalandepileptic pages 9-11)

The most directly applicable abstract conclusion from the 2023 prospective study is: “Genetic aetiologies are the most common cause of early-infantile developmental and epileptic encephalopathies… Patients with vitamin responsive epilepsies had the best probability of seizure control.” (Published September 2023; https://doi.org/10.1093/braincomms/fcad243.) (agarwala2023earlyinfantiledevelopmentaland pages 1-3)

Major limitations are small rare-disease cohorts, tertiary-center referral bias, changing terminology, pooling of mechanistically different disorders, sparse long-term adult data, and predominantly observational evidence for precision treatments. Exact OMIM, MONDO, Orphanet, HPO, NCIT, HGNC, and ClinVar identifiers should be validated against current database releases before production ingestion.

References

(agarwala2023earlyinfantiledevelopmentaland pages 4-6): Pooja Agarwala, Bhuvandeep Narang, Thenral S. Geetha, Nilesh Kurwale, Praveena L Samson, Tamanna Golani, Udita Mahadevia, Ramprasad Vedam, Sakthivel Murugan, Sagnik Chatterjee, Pradeep Goyal, and Vivek Jain. Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes—a prospective observational study. Brain Communications, Sep 2023. URL: https://doi.org/10.1093/braincomms/fcad243, doi:10.1093/braincomms/fcad243. This article has 17 citations and is from a peer-reviewed journal.
(agarwala2023earlyinfantiledevelopmentaland pages 1-3): Pooja Agarwala, Bhuvandeep Narang, Thenral S. Geetha, Nilesh Kurwale, Praveena L Samson, Tamanna Golani, Udita Mahadevia, Ramprasad Vedam, Sakthivel Murugan, Sagnik Chatterjee, Pradeep Goyal, and Vivek Jain. Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes—a prospective observational study. Brain Communications, Sep 2023. URL: https://doi.org/10.1093/braincomms/fcad243, doi:10.1093/braincomms/fcad243. This article has 17 citations and is from a peer-reviewed journal.
(scheffer2024developmentalandepileptic pages 34-39): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.
(agarwala2023earlyinfantiledevelopmentaland pages 8-10): Pooja Agarwala, Bhuvandeep Narang, Thenral S. Geetha, Nilesh Kurwale, Praveena L Samson, Tamanna Golani, Udita Mahadevia, Ramprasad Vedam, Sakthivel Murugan, Sagnik Chatterjee, Pradeep Goyal, and Vivek Jain. Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes—a prospective observational study. Brain Communications, Sep 2023. URL: https://doi.org/10.1093/braincomms/fcad243, doi:10.1093/braincomms/fcad243. This article has 17 citations and is from a peer-reviewed journal.
(scheffer2024developmentalandepileptic pages 9-11): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.
(scheffer2024developmentalandepileptic pages 19-21): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.
(specchio2024theexpandingfield pages 8-11): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.
(specchio2024theexpandingfield pages 6-8): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.
(scheffer2024developmentalandepileptic pages 11-13): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.
(scheffer2024developmentalandepileptic pages 13-15): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.
(nguyen2024genotypedriventherapeuticsin pages 9-10): Yen Thi My Nguyen, Bao-Quoc Vu, Duy-Khai Nguyen, Ngoc-Vinh Quach, Liem Thanh Bui, Jeonghan Hong, and Chi-Bao Bui. Genotype-driven therapeutics in dee and metabolic epilepsy: navigating treatment efficacy and drug resistance. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72683-7, doi:10.1038/s41598-024-72683-7. This article has 5 citations and is from a peer-reviewed journal.
(scheffer2024developmentalandepileptic pages 17-19): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.
(specchio2024theexpandingfield pages 27-29): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.
(specchio2024theexpandingfield pages 14-17): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.
(specchio2024theexpandingfield pages 1-6): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Definitions

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

Early-Infantile Developmental and Epileptic Encephalopathy (EIDEE): Research Report

Executive summary

1. Disease information

Definition and nomenclature

2. Etiology, risk, and protective factors

Genetic risk

Environmental, lifestyle, infectious, and protective factors

3. Phenotypes and quality-of-life impact

4. Genetic and molecular information

5. Mechanism and pathophysiology

6. Anatomy

7. Temporal development and natural history

8. Epidemiology, inheritance, and population

9. Diagnosis

Recommended workflow

Differential diagnosis

10. Outcomes and prognosis

11. Treatment and real-world implementation

Acute and conventional treatment

Genotype/etiology-guided treatment

12. 2023–2024 research developments and trials

13. Prevention

14. Other species and natural disease

15. Model organisms

Evidence limitations and authoritative interpretation

Artifacts